<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ondansetron: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ondansetron: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ondansetron: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9719" href="/d/html/9719.html" rel="external">see "Ondansetron: Drug information"</a> and <a class="drug drug_patient" data-topicid="10926" href="/d/html/10926.html" rel="external">see "Ondansetron: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F203706"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Zofran;</li>
<li>Zuplenz [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867761"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACCEL-Ondansetron;</li>
<li>ACCEL-Ondansetron ODT;</li>
<li>APO-Ondansetron;</li>
<li>ATHENA-Ondansetron ODT;</li>
<li>AURO-Ondansetron;</li>
<li>Auro-Ondansetron ODT;</li>
<li>CCP-Ondansetron [DSC];</li>
<li>JAMP Ondansetron;</li>
<li>JAMP-Ondansetron;</li>
<li>Mar-Ondansetron;</li>
<li>MAR-Ondansetron ODT;</li>
<li>MINT-Ondansetron;</li>
<li>MINT-Ondansetron ODT;</li>
<li>MYLAN-Ondansetron;</li>
<li>NAT-Ondansetron;</li>
<li>Ondansetron ODT;</li>
<li>Ondissolve ODF;</li>
<li>PMS-Ondansetron;</li>
<li>PMS-Ondansetron ODT;</li>
<li>SANDOZ Ondansetron;</li>
<li>TEVA Ondansetron;</li>
<li>Zofran ODT;</li>
<li>Zofran [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1060735"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">5-HT<sub>3</sub> Receptor Antagonist</span>;</li>
<li>
<span class="list-set-name">Antiemetic</span></li></ul></div>
<div class="block dop drugH1Div" id="F203733"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="170299cf-a590-4ce2-b509-66903788defc">Chemotherapy-induced nausea and vomiting, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced nausea and vomiting, prevention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Use in combination with or without dexamethasone and aprepitant or fosaprepitant depending upon patient age, chemotherapy emetogenic potential, and drug-interaction profile; dosing regimens variable, refer to specific protocols or institutional guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-36221901','lexi-content-ref-37178438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-36221901','lexi-content-ref-37178438'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Multiple-daily dose regimen (high, moderate, low emetic potential):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed dosing:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents: IV, Oral: 0.15 mg/kg/dose (5 mg/<b>m<sup>2</sup></b>/dose); maximum single dose: 16 mg/dose; administer first dose before the start of chemotherapy and then every 4 to 12 hours, not to exceed 3 doses; maximum daily dose: 0.45 mg/kg/<b>day</b> or 32 mg/<b>day</b>; whichever is less; higher emetogenic potential chemotherapy will require more frequent administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15804995','lexi-content-ref-8424909','lexi-content-ref-26795844','lexi-content-ref-23512831','lexi-content-ref-33754455','lexi-content-ref-10370357','lexi-content-ref-10989464','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15804995','lexi-content-ref-8424909','lexi-content-ref-26795844','lexi-content-ref-23512831','lexi-content-ref-33754455','lexi-content-ref-10370357','lexi-content-ref-10989464','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dosing:</p>
<p style="text-indent:-2em;margin-left:8em;">Children 4 to 11 years: Oral: 4 mg beginning 30 minutes before chemotherapy; repeat 4 and 8 hours after initial dose, then 4 mg every 8 hours for 1 to 2 days after chemotherapy completed.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Oral: 8 mg beginning 30 minutes before chemotherapy; repeat dose 8 hours after initial dose, then 8 mg every 12 hours for 1 to 2 days after chemotherapy completed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-daily dose regimen (low, moderate, or highly emetogenic potential): </i>Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IV: 0.3 to 0.45 mg/kg/dose once daily; maximum dose: 16 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11054974','lexi-content-ref-16404740','lexi-content-ref-33754455']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11054974','lexi-content-ref-16404740','lexi-content-ref-33754455'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="67a8ed02-f591-437c-8382-2fa0cb228e04">Cyclic vomiting syndrome, supportive/rescue therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cyclic vomiting syndrome, supportive/rescue therapy: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: IV: 0.3 to 0.4 mg/kg/dose every 4 to 6 hours as needed; maximum dose: 8 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31241819','lexi-content-ref-31540764','lexi-content-ref-26770896','lexi-content-ref-30076469','lexi-content-ref-Maqbool.1','lexi-content-ref-18728540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31241819','lexi-content-ref-31540764','lexi-content-ref-26770896','lexi-content-ref-30076469','lexi-content-ref-Maqbool.1','lexi-content-ref-18728540'])">Ref</a></span>). Maximum daily dose: 32 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26795844','lexi-content-ref-Nexus.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26795844','lexi-content-ref-Nexus.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f57e6ad3-046c-45be-a4b9-124e0d5a8e99">Gastroenteritis, acute; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroenteritis, acute; treatment:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32471647','lexi-content-ref-32132152','lexi-content-ref-36221901']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32471647','lexi-content-ref-32132152','lexi-content-ref-36221901'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Infants and Children: IV: 0.15 or 0.3 mg/kg/dose once; maximum dose: 16 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18762604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18762604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: <b>Note:</b> May repeat dose if patient vomits within 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30702253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30702253'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥3 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;15 kg: Oral: 0.2 mg/<b>kg</b>/dose once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28882877']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28882877'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">15 to 30 kg: Oral: 4 mg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28882877']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28882877'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;30 kg: Oral: 8 mg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28882877']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28882877'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae1bcfa5-9563-4c6b-a1af-01aa4e2e9d9d">Postoperative nausea and vomiting, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative nausea and vomiting, prevention: Note:</b> Administer immediately before or following induction of anesthesia, or postoperatively if the patient is symptomatic. Repeat doses administered in response to inadequate control of nausea/vomiting from preoperative doses are generally ineffective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32467512']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32467512'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: IV: 0.05 to 0.1 mg/kg/dose as a single dose; maximum dose: 4 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32467512','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32467512','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: IM, IV: 4 mg/dose as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32467512','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32467512','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8e20dc0f-ab29-4041-bfb4-ee8f8d796cda">Radiation-induced nausea and vomiting, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Radiation-induced nausea and vomiting, prevention:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Weight-directed dosing: Infants ≥5 months, Children, and Adolescents: Oral: 0.2 mg/kg/dose (maximum dose: 8 mg/dose) administered every 8 hours throughout total body irradiation (TBI) prior to hematopoietic stem cell transplant (HSCT) (n=68; mean age: 6.7 years; range: 5 months to 20 years); doses were generally rounded to 4 mg/dose in children 4 to 11 years and 8 mg/dose in children ≥12 years and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9578303']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9578303'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Alternate weight-based dosing: Children and Adolescents: Oral: 0.15 mg/kg/dose administered 3 to 4 times daily throughout TBI (n=33; mean age: 9 years; range: 13 months to 16 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9703004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9703004'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Fixed dose: <b>Note:</b> Derived from rounding weight-based (0.2 mg/kg/dose) doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9578303']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9578303'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children 4 to 11 years: Oral: 4 mg every 8 hours throughout TBI prior to HSCT.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: Oral: 8 mg every 8 hours throughout TBI prior to HSCT.</p>
<p style="text-indent:-2em;margin-left:6em;">Alternate fixed-dosing: Children ≥9 years and Adolescents: Oral: 8 mg every 12 hours on days of TBI prior to bone marrow transplantation (age range: 9 to 67 years; median age range: 39 to 49 years). <b>Note:</b> Administered in combination with dexamethasone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12180111']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12180111'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51150983"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: IV, Oral: No dose adjustments likely to be necessary, as clearance by the kidney accounts for only 5% of total clearance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7586904','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7586904','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51196548"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no pediatric-specific recommendations; based on experience in adult patients, no adjustment may be necessary for mild to moderate hepatic impairment; for severe impairment, dosing adjustment suggested.</p></div>
<div class="block doa drugH1Div" id="F203710"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9719" href="/d/html/9719.html" rel="external">see "Ondansetron: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Single IV doses &gt;16 mg are no longer recommended due to the potential for QT prolongation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>). Avoid use in patients with congenital long-QT syndrome.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5f0c4e32-bc54-4507-ae62-439c164002be">Carcinoid syndrome-associated diarrhea, severe, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Carcinoid syndrome-</b>
<b>associated diarrhea, severe, refractory (alternative agent) (off-label use): </b>Based on limited data (case reports):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 8 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9849494']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9849494'])">Ref</a></span>) <b>or</b> 8 mg twice daily for 3 days, followed by a maintenance dose of 4 to 8 mg/day for 4 to 12 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23675671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23675671'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 4 to 8 mg every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7717328']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7717328'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="170299cf-a590-4ce2-b509-66903788defc">Chemotherapy-induced nausea and vomiting, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced nausea and vomiting, prevention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Single-day IV chemotherapy regimens:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Highly emetogenic chemotherapy </b>(&gt;90% risk of emesis [eg, cisplatin, breast cancer regimens that include an anthracycline combined with cyclophosphamide]):</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Day of chemotherapy:</i></b> Administer prior to chemotherapy <b>and</b> in combination with a neurokinin 1 (NK<sub>1</sub>) receptor antagonist, dexamethasone, and olanzapine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV:</b> 8 mg or 0.15 mg/kg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>). Maximum: 16 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Tablet formulations and oral solution:</i> 8 mg twice daily for 2 doses with the first dose administered prior to chemotherapy administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27664248'])">Ref</a></span>) <b>or</b> 24 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Oral soluble film</i> (Zuplenz: discontinued in the United States for &gt;1 year)<i>:</i> 24 mg (three 8 mg doses given together) as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Post-chemotherapy days:</i></b> 5-HT<sub>3</sub> receptor antagonist use is <b>not</b> necessary (other components of the antiemetic regimen are administered) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Moderately emetogenic chemotherapy (30% to 90% risk of emesis): <b>Carboplatin-based regimens:</b></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Day of chemotherapy: </i></b>Administer prior to chemotherapy <b>and</b> in combination with an NK<sub>1</sub> receptor antagonist and dexamethasone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV:</b> 8 mg or 0.15 mg/kg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>). Maximum: 16 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 8 mg twice daily for 2 doses with the first dose administered prior to chemotherapy administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Post-chemotherapy days:</i></b> 5-HT<sub>3</sub> receptor antagonist use is not necessary (other components of the antiemetic regimen may be administered) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Moderately emetogenic chemotherapy (30% to 90% risk of emesis): <b>Non-carboplatin-based regimens (alternative agent): </b></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> ASCO guidelines and MASCC/ESMO guidelines do not state a preference for which 5-HT3 receptor antagonist should be used in this setting; however, palonosetron may be preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26345982','lexi-content-ref-Hesketh.1','lexi-content-ref-24590374']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26345982','lexi-content-ref-Hesketh.1','lexi-content-ref-24590374'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Day of chemotherapy: </i></b>Administer prior to chemotherapy <b>and </b>in combination with dexamethasone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV:</b> 8 mg or 0.15 mg/kg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>). Maximum: 16 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 8 mg twice daily for 2 doses with the first dose administered prior to chemotherapy administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Post-chemotherapy days: </i></b>5-HT<sub>3</sub> receptor antagonist use is <b>not</b> necessary (other components of the antiemetic regimen may be administered) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>); however, if a first-generation 5-HT<sub>3</sub> receptor antagonist (eg, ondansetron, granisetron) was used on day 1 of chemotherapy rather than palonosetron, the first-generation 5-HT<sub>3</sub> receptor antagonist may be continued for post-chemotherapy emetic prophylaxis on days 2 and 3 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hesketh.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hesketh.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Low emetogenic risk (10% to 30% risk of emesis):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Single-agent ondansetron is an option for prophylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Day of chemotherapy: </i></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV:</b> 8 mg as a single dose prior to chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral (off-label):</b> 8 mg as a single dose prior to chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Post-chemotherapy days:</i></b> Prophylaxis is not necessary on subsequent days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Minimal emetogenic risk (&lt;10% risk of emesis):</b> Routine antiemetic prophylaxis is not generally necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>High-dose chemotherapy with stem or bone marrow transplant: </b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Day of chemotherapy:</i></b> Administer prior to chemotherapy <b>and</b> in combination with a neurokinin 1 (NK<sub>1</sub>) receptor antagonist, dexamethasone, with or without olanzapine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 8 mg or 0.15 mg/kg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>). Maximum: 16 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral: </b>24 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Oral chemotherapy agents:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>High/moderate emetogenic risk oral agent (≥30% risk of emesis): </b>Oral: 8 to 16 mg/day administered before chemotherapy and continued daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hesketh.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hesketh.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Low/minimal emetogenic risk oral agent (&lt;30% risk of emesis):</b> Oral: 8 to 16 mg/day on an as-needed basis only (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hesketh.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hesketh.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c03c6291-f5ee-4dbf-803a-dac2b3589c16">Gastroparesis, symptomatic treatment of nausea and vomiting</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroparesis, symptomatic treatment of nausea and vomiting (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients with persistent symptoms refractory to prokinetic therapy. No data available; recommendations for use and dose are based on expert opinion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 4 to 8 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23147521','lexi-content-ref-Camilleri.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23147521','lexi-content-ref-Camilleri.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="683547c2-9905-454f-9d60-d2326a9e1ecd">Nausea and/or vomiting, acute, severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea and/or vomiting, acute, severe (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Use has primarily been evaluated in patients with undifferentiated nausea/vomiting presenting to the emergency department; however, may also use for nausea/vomiting due to viral gastroenteritis, acute mountain sickness, cyclical vomiting syndrome, palliative care, and a variety of other medical conditions associated with severe, self-limiting acute nausea/vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28318209','lexi-content-ref-Alexandraki.2019','lexi-content-ref-31241819','lexi-content-ref-Gallagher.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28318209','lexi-content-ref-Alexandraki.2019','lexi-content-ref-31241819','lexi-content-ref-Gallagher.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV, IM:</b> 4 to 8 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31241819','lexi-content-ref-20825792','lexi-content-ref-18304050','lexi-content-ref-24818542','lexi-content-ref-20022195','lexi-content-ref-21691464','lexi-content-ref-21091329']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31241819','lexi-content-ref-20825792','lexi-content-ref-18304050','lexi-content-ref-24818542','lexi-content-ref-20022195','lexi-content-ref-21691464','lexi-content-ref-21091329'])">Ref</a></span>); may repeat 4 to 8 mg every 4 to 8 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28318209','lexi-content-ref-31241819','lexi-content-ref-18573994']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28318209','lexi-content-ref-31241819','lexi-content-ref-18573994'])">Ref</a></span>). <b>Note:</b> For parenteral therapy, IV administration is preferred over IM when possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21091329']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21091329'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1fec3b37-3e64-424c-a849-4e0fe4d40b2c">Nausea and vomiting, pregnancy associated, severe or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<b>Nausea and vomiting, pregnancy associated, severe or refractory (off-label use)</b>: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be considered for adjunctive treatment of nausea and vomiting when symptoms persist following initial pharmacologic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29266076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29266076'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Patients without hypovolemia:</i></b>Oral, IV (bolus): 4 mg every 8 hours, as needed, added to current treatment regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24807340','lexi-content-ref-29266076','lexi-content-ref-25198265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24807340','lexi-content-ref-29266076','lexi-content-ref-25198265'])">Ref</a></span>). If necessary, some experts increase to a maximum of 8 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20942670','lexi-content-ref-Smith.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20942670','lexi-content-ref-Smith.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Patients with hypovolemia:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For patients with persistent symptoms despite intravenous fluid replacement:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 8 mg administered over 15 minutes every 12 hours, added to current treatment regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29266076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29266076'])">Ref</a></span>). Some experts use 4 to 8 mg administered as an IV bolus every 8 hours until stabilization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Smith.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Smith.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae1bcfa5-9563-4c6b-a1af-01aa4e2e9d9d">Postoperative nausea and vomiting, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative nausea and vomiting, prevention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Moderate- to high-risk patients: </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>In patients at moderate risk, may combine ondansetron with other prophylactic interventions (eg, another antiemetic agent from a different pharmacologic class, modification of anesthetic technique, acupuncture); in patients at high risk, combine 3 or more interventions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15190136','lexi-content-ref-Feinleib.1','lexi-content-ref-24356162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15190136','lexi-content-ref-Feinleib.1','lexi-content-ref-24356162'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Usual dose:</b> IV: 4 mg as a single dose at the end of surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24356162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24356162'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Alternative strategy:</b> Oral (oral disintegrating tablet or oral soluble film [Zuplenz: discontinued in the United States for &gt;1 year]): 8 mg as a single dose given 30 to 60 minutes prior to surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19453311','lexi-content-ref-1386523','lexi-content-ref-24356162','lexi-content-ref-33075160']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19453311','lexi-content-ref-1386523','lexi-content-ref-24356162','lexi-content-ref-33075160'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Low-risk patients:</i></b>Although prophylaxis is not always indicated in low-risk patients, consensus guidelines acknowledge that some experts may administer an antiemetic in these patients; however, clinicians are also advised that this strategy comes with the potentially unnecessary risk of rare adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24356162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24356162'])">Ref</a></span>). If ondansetron is given, the dosing is the same as for moderate- to high-risk patients.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Post-discharge management in high-risk patients: </i></b>Limited data available; dosage regimen studied in a single clinical trial:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral</b> (oral disintegrating tablet or oral soluble film [Zuplenz: discontinued in the United States for &gt;1 year]): 8 mg to be taken on discharge and in the morning of postoperative days 1 and 2 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18633020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18633020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="01cc9a62-afb1-49b1-9522-dcaaae6b89b3">Postoperative nausea and vomiting, treatment or rescue therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative nausea and vomiting, treatment or rescue therapy (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Rescue therapy should always include an antiemetic from a different class than the one used for prophylaxis, unless a potentially inadequate dose was initially administered or the effect of the first drug has worn off (&gt;6 hours since initial dose for most 5-HT<sub>3</sub> receptor antagonists) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Feinleib.1','lexi-content-ref-24356162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Feinleib.1','lexi-content-ref-24356162'])">Ref</a></span>). However, some experts do not recommend repeat administration of a 5-HT<sub>3</sub> antagonist unless no alternatives are available for rescue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32467512']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32467512'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 4 mg as a single dose when a prophylactic agent was not utilized (treatment) or following failure of an agent utilized as prophylaxis (rescue therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32467512','lexi-content-ref-24356162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32467512','lexi-content-ref-24356162'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral</b> (oral disintegrating tablet or oral soluble film [Zuplenz: discontinued in the United States for &gt;1 year]): 4 or 8 mg as a single dose when a prophylactic agent was not utilized (treatment) or following failure of an agent utilized as prophylaxis (rescue therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32467512','lexi-content-ref-34560688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32467512','lexi-content-ref-34560688'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c7be2baf-f6a5-4ddd-823d-3858ab50dd87">Radiation therapy–associated nausea and vomiting, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Radiation therapy–associated nausea and vomiting, prevention: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>High-emetogenic risk radiation therapy (total body irradiation): </b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Radiation day(s):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV</b>
<b>(off-label):</b> 8 mg or 0.15 mg/kg (maximum: 16 mg/dose)(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>) once daily or twice daily prior to each fraction of radiation; administer in combination with dexamethasone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 8 mg once daily or twice daily administered 1 to 2 hours prior to each fraction of radiation; administer in combination with dexamethasone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>) <b>or</b>, in one clinical trial of 4 days of hyperfractionated total body irradiation, 8 mg (without dexamethasone) was administered 1.5 hours prior to every fraction of radiation (3 times daily for the first 3 days and twice daily on day 4) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10918432']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10918432'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Post-radiation days: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV (off-label),</b>
<b>Oral</b>: The appropriate duration of therapy following radiotherapy days is not well defined; ASCO guidelines recommend continuing ondansetron once daily or twice daily on the day after each day of radiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Moderate-emetogenic risk radiation therapy (upper abdomen, craniospinal irradiation) (off-label use): </b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Radiation day(s):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV (off-label):</b> 8 mg <b>or</b> 0.15 mg/kg (maximum: 16 mg/dose [manufacturer's labeling]) once daily or twice daily prior to each fraction of radiation; may administer with or without dexamethasone before the first 5 fractions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 8 mg once daily or twice daily administered 1 to 2 hours prior to each fraction of radiation; may administer with or without dexamethasone before the first 5 fractions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>) <b>or, </b>in clinical trials involving upper abdomen radiation (high-dose single exposure or multiple-day fractionated course), 8 mg 3 times daily (without dexamethasone) has been given; doses were administered 1 to 2 hours prior to radiation therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1702012','lexi-content-ref-8305355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1702012','lexi-content-ref-8305355'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Low- (brain, head and neck, thorax, pelvis) to minimal- (extremities, breast) emetogenic risk radiation therapy:</b></i>Routine prophylaxis <b>not</b> recommended; however, may use as rescue therapy using the following dosing with consideration of using prophylactically for the remainder of radiation therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Feyer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Feyer.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 8 mg or 0.15 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>) (maximum: 16 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>)).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 8 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6d7aa28a-a77d-4dd4-99bc-967afb9895d7">Vertigo-associated nausea and vomiting</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vertigo-associated nausea and vomiting (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (preferred), IM:</b> 4 to 8 mg once for acute symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Furman.2018','lexi-content-ref-30268346']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Furman.2018','lexi-content-ref-30268346'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 4 mg every 8 to 12 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Furman.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Furman.2018'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990826"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: IV, Oral:</b> No dose adjustments likely to be necessary, as clearance by the kidney accounts for only 5% of total clearance (Roila 1995; manufacturer’s labeling). Unlikely to be significantly dialyzed due to relatively high volume of distribution and plasma protein binding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988038"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:0em;">Severe impairment (Child-Pugh class C):</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Day 1: Maximum daily dose: 8 mg; however, according to the manufacturer, there is no experience beyond first-day administration (has not been studied beyond day 1)</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Maximum daily dose: 8 mg</p></div>
<div class="block arsc drugH1Div" id="F54962546"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Constipation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ondansetron may commonly cause<b> constipation</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24334242','lexi-content-ref-9006746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24334242','lexi-content-ref-9006746'])">Ref</a></span>). Rare cases of <b>intestinal obstruction</b> have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25461913','lexi-content-ref-9358948']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25461913','lexi-content-ref-9358948'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Likely due to blockade of 5-HT3 gut receptors which results in decreased motility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15915460']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15915460'])">Ref</a></span>). May also occur as a result of decreased colonic transit time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2151757','lexi-content-ref-2138532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2151757','lexi-content-ref-2138532'])">Ref</a></span>) and inhibition of postprandial increase in tone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12100220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12100220'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; one reported case of constipation occurred the same day as oral ondansetron administration; intestinal obstruction resulted approximately 2 weeks after continuous twice daily dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9358948']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9358948'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting liver disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15813840','lexi-content-ref-16009690','lexi-content-ref-15915460']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15813840','lexi-content-ref-16009690','lexi-content-ref-15915460'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Headache</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Headache</b> is the most reported adverse reaction with ondansetron (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12585731','lexi-content-ref-8265095']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12585731','lexi-content-ref-8265095'])">Ref</a></span>). Additional doses and movement (with or without postural changes) have been associated with worsening (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12585731','lexi-content-ref-20043218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12585731','lexi-content-ref-20043218'])">Ref</a></span>). Severe headache has led to discontinuation in reported cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7664768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7664768'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; severe headache reported to occur within minutes of administration, often lasting minutes to hours. There have been multiple case reports of children experiencing throbbing headaches for several days following ondansetron and chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25684821','lexi-content-ref-12585731','lexi-content-ref-20661681']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25684821','lexi-content-ref-12585731','lexi-content-ref-20661681'])">Ref</a></span>). One patient reported onset of severe headache occurring within 2 hours of the first dose and continued to occur every 12 hours following repeated administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20043218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20043218'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Personal or family history of migraine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12585731','lexi-content-ref-20661681']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12585731','lexi-content-ref-20661681'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of propofol and/or fentanyl (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25684821','lexi-content-ref-12585731','lexi-content-ref-20661681']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25684821','lexi-content-ref-12585731','lexi-content-ref-20661681'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1485179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1485179'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity (immediate)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immediate <b>hypersensitivity reactions</b> may occur with ondansetron, including <b>urticaria</b>, <b>angioedema</b>,<b> hypotension</b>, <b>bronchospasm</b>, <b>dyspnea,</b> and <b>anaphylaxis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15727597','lexi-content-ref-8379613','lexi-content-ref-20921907','lexi-content-ref-19151059','lexi-content-ref-26182691','lexi-content-ref-28866307','lexi-content-ref-7803876','lexi-content-ref-24565629','lexi-content-ref-11575988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15727597','lexi-content-ref-8379613','lexi-content-ref-20921907','lexi-content-ref-19151059','lexi-content-ref-26182691','lexi-content-ref-28866307','lexi-content-ref-7803876','lexi-content-ref-24565629','lexi-content-ref-11575988'])">Ref</a></span>). Some patients may only present with hypotension, without any accompanying symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19151059','lexi-content-ref-26555872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19151059','lexi-content-ref-26555872'])">Ref</a></span>). Patients may have more severe reactions on subsequent exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26555872','lexi-content-ref-8596322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26555872','lexi-content-ref-8596322'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non-dose-related; immunologic; likely IgE-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19151059','lexi-content-ref-28866307']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19151059','lexi-content-ref-28866307'])">Ref</a></span>); may be the result of direct mast cell stimulation (in some patients without previous exposure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8379613','lexi-content-ref-11575988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8379613','lexi-content-ref-11575988'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; immediate hypersensitivity reactions generally occur within 1 hour of administration, but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-NICE.2014'])">Ref</a></span>). Reactions usually occur after the first dose during the second or third course of chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8379613']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8379613'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Adults with cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8379613','lexi-content-ref-8596322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8379613','lexi-content-ref-8596322'])">Ref</a></span>); however, a few isolated cases have been reported in children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20921907','lexi-content-ref-21679335']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20921907','lexi-content-ref-21679335'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• IV route of administration; however, anaphylaxis following sublingual administration has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21679335']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21679335'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reaction between serotonin 5-HT<sub>3</sub> antagonists has been described in limited case reports (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18503688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18503688'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">QT prolongation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Increases in ECG intervals (eg, PR, QRS duration, JT); <b>prolonged QT interval on ECG;</b> and <b>bradycardia</b> have been observed with ondansetron (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27729680']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27729680'])">Ref</a></span>). Cases of ventricular arrhythmias and <b>torsades de pointes</b> have also been reported. Rare cases of fatalities have occurred even at low doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20040955','lexi-content-ref-24314899','lexi-content-ref-29259513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20040955','lexi-content-ref-24314899','lexi-content-ref-29259513'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: QT prolongation may occur due to HERG K+ channel-blockade (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27729680']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27729680'])">Ref</a></span>). Suppression of autonomic reflexes may contribute to bradycardia, hypotension, and tachyarrhythmias (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20040955','lexi-content-ref-22046106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20040955','lexi-content-ref-22046106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; usually occurs 1 to 2 hours after administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12921512']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12921512'])">Ref</a></span>); however, QT prolongation peaks have been observed within ~5 to 15 minutes following administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18648229','lexi-content-ref-23716765','lexi-content-ref-26720490']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18648229','lexi-content-ref-23716765','lexi-content-ref-26720490'])">Ref</a></span>). QTc intervals &gt;500 ms have been recorded within 15 minutes after administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15915019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15915019'])">Ref</a></span>). May persist &gt;2 hours from administered dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716765'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• IV route of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24314899']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24314899'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Single doses &gt;16 mg IV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29259513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29259513'])">Ref</a></span>); however, risk should be considered even with low IV doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24314899','lexi-content-ref-24803784']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24314899','lexi-content-ref-24803784'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant medications that prolong the QT interval (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24314899','lexi-content-ref-22046106','lexi-content-ref-31428390','lexi-content-ref-27387786']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24314899','lexi-content-ref-22046106','lexi-content-ref-31428390','lexi-content-ref-27387786'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22046106','lexi-content-ref-29259513','lexi-content-ref-31428390','lexi-content-ref-27387786']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22046106','lexi-content-ref-29259513','lexi-content-ref-31428390','lexi-content-ref-27387786'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypothermia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18648229','lexi-content-ref-31428390']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18648229','lexi-content-ref-31428390'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant volatile anesthetics or cumulative high-dose anthracycline therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18648229','lexi-content-ref-24314899','lexi-content-ref-22046106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18648229','lexi-content-ref-24314899','lexi-content-ref-22046106'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Underlying heart disease including heart failure or acute coronary syndromes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24314899','lexi-content-ref-22046106','lexi-content-ref-27387786']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24314899','lexi-content-ref-22046106','lexi-content-ref-27387786'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Electrolyte abnormalities (eg, hypokalemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22046106','lexi-content-ref-29259513','lexi-content-ref-31428390','lexi-content-ref-27387786']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22046106','lexi-content-ref-29259513','lexi-content-ref-31428390','lexi-content-ref-27387786'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of QT prolongation, bradycardia, tachycardia, or cardiac rhythm disorders (especially ventricular arrhythmia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24314899','lexi-content-ref-22046106','lexi-content-ref-29259513','lexi-content-ref-29317399','lexi-content-ref-31428390','lexi-content-ref-27387786']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24314899','lexi-content-ref-22046106','lexi-content-ref-29259513','lexi-content-ref-29317399','lexi-content-ref-31428390','lexi-content-ref-27387786'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients receiving ondansetron following anesthesia, while in the intensive care unit, or during hospital admission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22046106','lexi-content-ref-24803784','lexi-content-ref-27387786']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22046106','lexi-content-ref-24803784','lexi-content-ref-27387786'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F203673"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidence reported in adult patients unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (9% to 11%)<span class="lexi-table-link-container"> (<a aria-label="Constipation table link" class="lexi-table-link" data-table-id="lexi-content-constipation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-constipation')">table 1</a>)</span><span class="table-link" style="display:none;">Constipation</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Constipation" frame="border" id="lexi-content-constipation" rules="all">
<caption style="text-align:center;">
<b>Ondansetron: Adverse Reaction: Constipation</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ondansetron)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ondansetron)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Chemotherapy-induced nausea and vomiting</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">242</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Injection</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system<b>: </b>Fatigue (oral: ≤13%), headache (9% to 24%)<span class="lexi-table-link-container"> (<a aria-label="Headache table link" class="lexi-table-link" data-table-id="lexi-content-headache" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-headache')">table 2</a>)</span><span class="table-link" style="display:none;">Headache</span>, malaise (oral: ≤13%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Headache" frame="border" id="lexi-content-headache" rules="all">
<caption style="text-align:center;">
<b>Ondansetron: Adverse Reaction: Headache</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ondansetron)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Metoclopramide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ondansetron)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Metoclopramide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Chemotherapy-induced nausea and vomiting</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">242</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.15 mg/kg x 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Injection</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Chemotherapy-induced nausea and vomiting</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">419</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">156</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">34</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 mg single dose</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IV</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Postoperative nausea and vomiting</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">547</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">547</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">16 mg single dose</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Postoperative nausea and vomiting</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">550</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">531</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (2% to 5%), skin rash (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (oral: 6%; IV: children 1 to 24 months of age: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Gynecologic disease (oral: 7%), urinary retention (oral: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (&gt;2 times ULN: 1% to 5%; transient), increased serum aspartate aminotransferase (&gt;2 times ULN: 1% to 5%; transient)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (&lt;2%) (Fernando 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (4%; includes burning sensation at injection site, erythema at injection site, injection site pain)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (oral: ≤6%), anxiety (oral: ≤6%), dizziness (7%), drowsiness (IV: ≤8%), paresthesia (IV: 2%), sedated state (IV: ≤8%), sensation of cold (IV: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm (&lt;2%), hypoxia (oral: 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (2% to 8%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Extrapyramidal reaction (Ritter 2003; Sprung 2003)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris, peripheral vascular disease, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Tonic clonic epilepsy</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (Havrilla 2009), bradycardia (Afonso 2009; Rapp 2015), depression of ST segment on ECG, flushing, ischemic heart disease (most commonly due to coronary artery spasm and may occur with oral or IV [predominantly IV]; occurred immediately after IV administration and resolved with treatment), palpitations, prolonged QT interval on ECG (Ganjare 2013; Moffett 2016), second degree atrioventricular block, supraventricular tachycardia, syncope, torsades de pointes (Lee 2017; Patel 2019), ventricular premature contractions, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stevens-Johnson syndrome, toxic epidermal necrolysis (Saraogi 2012), urticaria (Bousquet 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Hiccups<b>,</b> intestinal obstruction (Cohen 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Positive lymphocyte transformation test</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, fixed drug eruption (Maitra 2017), hypersensitivity reaction (Garcia Nunez 2015; Leung 2013), nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dystonic reaction (Diaz-Parlet 2015), serotonin syndrome (George 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Laryngospasm</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Accommodation disturbance, oculogyric crisis (Macachor 2014), transient blindness (lasted ≤48 hours) (Cherian 2005), transient blurred vision (following infusion)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, laryngeal edema, stridor</p></div>
<div class="block coi drugH1Div" id="F203687"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to ondansetron or any component of the formulation; concomitant use with apomorphine</p></div>
<div class="block war drugH1Div" id="F203670"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Serotonin syndrome: Serotonin syndrome (SS) has been reported with 5-HT<sub>3</sub> receptor antagonists, predominantly when used in combination with other serotonergic agents (eg, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and/or methylene blue). Some of the cases have been fatal. The majority of serotonin syndrome reports due to 5-HT<sub>3</sub> receptor antagonist have occurred in a postanesthesia setting or in an infusion center. SS has also been reported following overdose of ondansetron. Signs/symptoms of SS include mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile BP, diaphoresis, dizziness, flushing, hyperthermia); neuromuscular changes (eg, tremor, rigidity, myoclonus, hyperreflexia, incoordination); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: Orally disintegrating tablets contain phenylalanine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Chemotherapy-associated emesis: Antiemetics are most effective when used prophylactically (MASCC/ESMO [Roila 2016]). If emesis occurs despite optimal antiemetic prophylaxis, re-evaluate emetic risk, disease status, concurrent morbidities and current medications to assure antiemetic regimen is optimized (ASCO [Hesketh 2020]).</p></div>
<div class="block prod-avail drugH1Div" id="F57558402"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Zuplenz has been discontinued in the United States for &gt;1 year.</p></div>
<div class="block foc drugH1Div" id="F203680"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Film, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zuplenz: 4 mg (30 ea [DSC]); 8 mg (30 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg/2 mL (2 mL); 40 mg/20 mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg/2 mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg/5 mL (5 mL, 50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg/2 mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zofran: 4 mg, 8 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg, 8 mg, 24 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg, 8 mg</p></div>
<div class="block geq drugH1Div" id="F203666"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F203689"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ondansetron HCl Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg/2 mL (per mL): $0.28 - $1.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/20 mL (per mL): $0.30 - $1.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ondansetron HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg/5 mL (per mL): $4.78 - $6.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Ondansetron HCl Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg/2 mL (per mL): $1.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (Ondansetron Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $22.25 - $23.11</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg (per each): $36.66 - $38.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ondansetron HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $0.54 - $24.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg (per each): $0.64 - $41.53</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">24 mg (per each): $106.51</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867762"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Film, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ondissolve ODF: 4 mg (6 ea, 10 ea, 50 ea); 8 mg (6 ea, 10 ea, 50 ea) [contains levomenthol, polyethylene glycol (macrogol), polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zofran: 2 mg/mL ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/mL (2 mL, 4 mL, 5 mL, 20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zofran: 4 mg/5 mL ([DSC]) [contains alcohol, usp, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg/5 mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zofran: 4 mg [DSC], 8 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg, 8 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zofran ODT: 4 mg, 8 mg [contains aspartame, methylparaben sodium, propylparaben sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg, 8 mg</p></div>
<div class="block exp drugH1Div" id="F203685"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Commercial oral solution is available (0.8 mg/mL)</p>
<p style="text-indent:0em;margin-top:2em;">If commercial oral solution is unavailable, a 0.8 mg/mL syrup may be made with ondansetron tablets, Ora-Plus® (Paddock), and any of the the following syrups: Cherry syrup USP, Syrpalta® (HUMCO), Ora-Sweet® (Paddock), or Ora-Sweet® Sugar-Free (Paddock). Crush ten 8 mg tablets in a mortar and reduce to a fine powder (flaking of the tablet coating occurs). Add 50 mL Ora-Plus® in 5 mL increments, mixing thoroughly; mix while adding the chosen syrup in incremental proportions to <b>almost</b> 100 mL; transfer to a calibrated bottle, rinse mortar with syrup, and add sufficient quantity of syrup to make 100 mL. Label "shake well" and "refrigerate". Stable for 42 days refrigerated (Trissel 1996).</p>
<p style="text-indent:0em;margin-top:2em;">Rectal suppositories: Calibrate a suppository mold for the base being used. Determine the displacement factor (DF) for ondansetron for the base being used (Fattibase® = 1.1; Polybase® = 0.6). Weigh the ondansetron tablet(s). Divide the tablet weight by the DF; this result is the weight of base displaced by the drug. Subtract the weight of base displaced from the calculated weight of base required for each suppository. Grind the ondansetron tablets in a mortar and reduce to a fine powder. Weigh out the appropriate weight of suppository base. Melt the base over a water bath (&lt;55°C). Add the ondansetron powder to the suppository base and mix well. Pour the mixture into the suppository mold and cool. Stable for at least 30 days refrigerated (Tenjarla 1998).</p>
<div class="reference">Tenjarla SN, Ward ES, and Fox JL, "Ondansetron Suppositories: Extemporaneous Preparation, Drug Release, Stability and Flux Through Rabbit Rectal Membrane," <i>Int J Pharm Compound</i>, 1998, 2(1):83-8.</div>
<div class="reference">Trissel LA, <i>Trissel's Stability of Compounded Formulations</i>, Washington, DC: American Pharmaceutical Association, 1996.</div>
</div>
<div class="block admp drugH1Div" id="F52613473"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May administer without regard to meals. For chemotherapy-induced nausea and vomiting, administer 30 minutes prior to chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dosage-form specific: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Orally disintegrating tablet (Zofran ODT): Do not remove from blister until needed. Peel backing off the blister; do not push tablet through foil backing. Using dry hands, place tablet on tongue and allow to dissolve; swallow with saliva (no need to administer with liquids).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral solution: Measure with a calibrated measuring device.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent infusion:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Chemotherapy-induced nausea and vomiting:</b> Infuse over 15 minutes.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Cyclic vomiting syndrome:</b> Infuse over 15 to 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8708870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8708870'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IV push: <b>Gastroenteritis, postoperative nausea/vomiting (PONV):</b> May be administered undiluted IV over 2 to 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21589830','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21589830','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Adolescents: <b>PONV:</b> Administer as undiluted injection.</p></div>
<div class="block adm drugH1Div" id="F203683"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Oral dosage forms should be administered 30 minutes prior to chemotherapy; 1 to 2 hours before radiation; 30 to 60 minutes prior to surgery or induction of anesthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablets: Do not remove from blister until needed. Peel backing off the blister, do not attempt to push tablet through the foil. Using dry hands, place tablet on tongue and allow to dissolve. Swallow with saliva (no need to administer with liquids).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral soluble film: Do not remove from pouch until immediately before use. Using dry hands, place film on top of tongue and allow to dissolve (4 to 20 seconds). Swallow with or without liquid. If using more than one film, each film should be allowed to dissolve completely before administering the next film.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Should be administered undiluted.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">IVPB: Infuse diluted solution over 15 minutes</p>
<p style="text-indent:-2em;margin-left:6em;">Chemotherapy-induced nausea and vomiting: Give first dose 30 minutes prior to beginning chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">IV push: Prevention of postoperative nausea and vomiting: Single doses may be administered IV injection as undiluted solution over at least 30 seconds but preferably over 2 to 5 minutes</p></div>
<div class="block sts drugH1Div" id="F203700"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Oral disintegrating tablet: Store between 2°C and 30°C (36°F and 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral soluble film: Store between 20°C and 25°C (68°F and 77°F). Store pouches in cartons; keep film in individual pouch until ready to use.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: Store upright in carton between 15°C and 30°C (59°F and 86°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet: Store between 2°C and 30°C (36°F and 86°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Vial: Store between 2°C and 30°C (36°F and 86°F). Protect from light. Chemically and physically stable when mixed in D5W or NS for 48 hours at room temperature; however, diluents generally do not contain a preservative and sterile precautions should be observed. After dilution, do not use beyond 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Premixed bag in D5W: Store at 20°C to 25°C (68°F to 77°F), excursions permitted from 15°C to 30°C (59°F to 86°F); may refrigerate; avoid freezing and excessive heat; protect from light.</p></div>
<div class="block usep drugH1Div" id="F53568105"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablets, oral solution, oral tablets: Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy (FDA approved in ages ≥4 years and adults); prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy (including cisplatin) (FDA approved in adults); prevention of nausea and vomiting associated with radiotherapy (FDA approved in adults); prevention of postoperative nausea and vomiting (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:4em;">Soluble Film (Zuplenz): Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy (FDA approved in ages ≥4 years and adults); prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy or radiotherapy (FDA approved in adults); prevention of postoperative nausea and vomiting (PONV) (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy (including high-dose cisplatin) (FDA approved in ages ≥6 months and adults); prevention of postoperative nausea and vomiting (FDA approved in ages ≥1 month and adults); has also been used in the treatment of acute gastroenteritis and cyclic vomiting syndrome.</p></div>
<div class="block mst drugH1Div" id="F203765"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ondansetron may be confused with dolasetron, granisetron, palonosetron </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zofran may be confused with Zantac, Zosyn</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F203750"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F203675"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May enhance the QTc-prolonging effect of Ondansetron. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of Ondansetron.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apomorphine: Antiemetics (5HT3 Antagonists) may enhance the hypotensive effect of Apomorphine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Ondansetron.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: Ondansetron may enhance the QTc-prolonging effect of Dabrafenib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: May enhance the QTc-prolonging effect of Ondansetron. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: Ondansetron may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: Ondansetron may enhance the QTc-prolonging effect of Haloperidol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: Ondansetron may increase the serum concentration of MetFORMIN. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Panobinostat: Ondansetron may enhance the arrhythmogenic effect of Panobinostat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): May enhance the QTc-prolonging effect of Ondansetron. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of Ondansetron.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of Ondansetron. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): Ondansetron may enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). Ondansetron may enhance the serotonergic effect of QT-prolonging Antidepressants (Moderate Risk). This could result in serotonin syndrome.  Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome when these agents are combined. Patients with additional risk factors for QTc prolongation or serotonin syndrome may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): Ondansetron may enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk).  Management: Monitor for QTc interval prolongation, ventricular arrhythmias, including torsades de pointes, when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IA Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of Ondansetron. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): May enhance the QTc-prolonging effect of Ondansetron. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class III Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of Ondansetron. Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): Ondansetron may enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): Ondansetron may enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): May enhance the QTc-prolonging effect of Ondansetron. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): Ondansetron may enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): Ondansetron may enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of Ondansetron. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Ondansetron may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tapentadol: Ondansetron may diminish the analgesic effect of Tapentadol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: Ondansetron may enhance the serotonergic effect of TraMADol. This could result in serotonin syndrome. Ondansetron may diminish the therapeutic effect of TraMADol.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and diminished tramadol efficacy when these agents are combined.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F203703"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Tablet: Food slightly increases the extent of absorption. Management: Administer without regard to meals.</p></div>
<div class="block dic drugH1Div" id="F203691"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain phenylalanine.</p></div>
<div class="block pri drugH1Div" id="F203690"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Ondansetron crosses the placenta (Elkomy 2014; Siu 2006).</p>
<p style="text-indent:0em;margin-top:2em;">Ondansetron can be detected in fetal tissue (Siu 2006). The risk of developing a major congenital malformation following first trimester exposure is under study. Risks related to specific birth defects (eg, cardiac anomalies, oral clefts) requires confirmation; available human data are conflicting (ACOG 2018; Dormuth 2021; Kaplan 2019; Lemon 2020; Lavecchia 2018; Picot 2020). Clearance is decreased immediately after birth in neonates exposed to ondansetron in utero (Elkomy 2014).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, clearance of ondansetron may increase as pregnancy progresses (Lemon 2016). Dose adjustment is not needed when administered for the prevention of nausea and vomiting associated with cesarean delivery (Elkomy 2014).</p>
<p style="text-indent:0em;margin-top:2em;">Ondansetron may be considered for the treatment of severe or refractory nausea and vomiting of pregnancy (NVP) when preferred agents have failed (ACOG 2018; Campbell 2016). Until additional information related to fetal safety is available, current guidelines suggest use prior to 10 weeks gestation be individualized (ACOG 2018). Dose-dependent QT-interval prolongation can occur with use; therefore, ECG monitoring is recommended in patients with risk factors for arrhythmia (ACOG 2018); this may include patients with electrolyte abnormalities associated with some cases of NVP (Koren 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Ondansetron may be considered as part of a multimodal approach to prevent nausea and vomiting associated with cesarean delivery. A combination of ≥2 antiemetics with different mechanisms of action is recommended to treat intraoperative and postoperative nausea and vomiting (Bollag 2021; Griffiths 2012; Habib 2013; Jetling 2017; Macones 2019; Zhou 2018).</p>
<p style="text-indent:0em;margin-top:2em;">An international consensus panel recommends that 5-HT<sub>3</sub> antagonists (including ondansetron) can be used when necessary in pregnant patients receiving chemotherapy for the treatment of gynecologic cancers (Amant 2019).</p></div>
<div class="block mopp drugH1Div" id="F53568106"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">ECG if applicable (eg, high-risk or elderly patients, concurrent use of other medications known to prolong QT interval, electrolyte abnormalities [hypokalemia or hypomagnesemia], heart failure, bradyarrhythmias, and cumulative high-dose anthracycline therapy); serum potassium and magnesium levels. Monitor for signs/symptoms of serotonin syndrome and hypersensitivity; monitor for decreased bowel activity (particularly in patients at risk for bowel obstruction). Monitor for signs/symptoms of myocardial ischemia.</p></div>
<div class="block pha drugH1Div" id="F203669"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ondansetron is a selective 5-HT<sub>3</sub>-receptor antagonist which blocks serotonin, both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone</p></div>
<div class="block phk drugH1Div" id="F203686"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: ~30 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: 100%; nonlinear absorption occurs with increasing oral doses; Zofran ODT tablets are bioequivalent to Zofran tablets; absorption does not occur via oral mucosa</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: Surgical patients:</p>
<p style="text-indent:-2em;margin-left:6em;">1 to 4 months: 3.5 L/kg</p>
<p style="text-indent:-2em;margin-left:6em;">5 to 24 months: 2.3 L/kg</p>
<p style="text-indent:-2em;margin-left:6em;">3 to 12 years: 1.65 L/kg</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Cancer patients: 4 to 18 years: 1.9 L/kg</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 1.9 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding, plasma: 70% to 76%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic via hydroxylation, followed by glucuronide or sulfate conjugation; CYP1A2, CYP2D6, and CYP3A4 substrate; some demethylation occurs</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: 50% to 70% due to some first-pass metabolism; in cancer patients (adults), 85% to 87% bioavailability possibly related to changes in metabolism</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children: Cancer patients: Children and Adolescents: 4 to 18 years: 2.8 hours; Surgical patients: Infants 1 to 4 months: 6.7 hours; Infants and Children 5 months to 12 years: 2.9 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 3 to 6 hours; Mild-to-moderate hepatic impairment (Child-Pugh classes A and B): 12 hours; Severe hepatic impairment (Child-Pugh class C): 20 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Oral: ~2 hours; Oral soluble film: ~1 hour</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (44% to 60% as metabolites, ~5% as unchanged drug); feces (~25%)</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance:</p>
<p style="text-indent:-2em;margin-left:4em;">Cancer patients: Children and Adolescents 4 to 18 years: 0.599 L/kg/hour</p>
<p style="text-indent:-2em;margin-left:4em;">Surgical patients: Infants and Children: 1 to 4 months: 0.401 L/kg/hour; 5 to 24 months: 0.581 L/kg/hour; 3 to 12 years: 0.439 L/kg/hour</p>
<p style="text-indent:-2em;margin-left:4em;">Adult (normal): 19 to 40 years: 0.381 L/kg/hour; 61 to 74 years: 0.319 L/kg/hour; &gt;75 years: 0.262 L/kg/hour</p></div>
<div class="block phksp drugH1Div" id="F51160047"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Mean plasma clearance is reduced by 41% (IV) and 50% (oral) in patients with severe renal impairment (CrCl &lt;30 mL/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In patients with mild to moderate impairment, clearance is reduced 2-fold and the mean half-life is increased to 11.6 hours (compared to 5.7 hours in subjects with normal hepatic function). Clearance is reduced 2- to 3-fold and the apparent V<sub>d</sub> is increased, and the half-life is increased to 20 hours in patients with severe hepatic impairment (Child-Pugh class C).</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: In elderly patients &gt;75 years of age, there is a reduction in clearance and an increase in elimination half-life.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: The extent and rate of absorption is greater in women than in men. There is slower clearance, a smaller volume of distribution, and higher bioavailability in women.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F203692"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Aurodanz | Danstro | Imatox | Ondansetron | Tesnad | Vomicure | Vomran | Zofran</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cetron | Dantenk | Emivox | Espasevit | Finaber | Finoxi | Nausedron | Ondansetron fabra | Ondansetron filaxis | Ondansetron gobbi | Ondansetron lazar | Ondansetron martian | Ondansetron northia | Ondansetron vannier | Ondansetron veinfar | Ondasentron Richet | Setron | Zofran</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ondansan | Ondansetron | Ondansetron actavis | Ondansetron b braun | Ondansetron b. braun | Ondansetron bluefish | Ondansetron hikma | Ondansetron interpharm | Ondansetron kabi | Ondansetron sandoz | Ondansetron stada | Zofran | Zofran zydis</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo ondansetron | Apx ondansetron | Ondansetron | Ondansetron alphapharm | Ondansetron an | Ondansetron apotex | Ondansetron claris | Ondansetron drla | Ondansetron gh | Ondansetron lupin | Ondansetron mylan | Ondansetron mylan odt | Ondansetron odt drla | Ondansetron Rl | Ondansetron sz | Ondansetron sz odt | Ondaz | Onsetron | Zilfojim | Zilfojim ODT | Zofran | Zondan | Zotren odt</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Anset | Apulset | Avona | Emeren | Emistat | Emiston | Nauset | Ofmit | Ofran | Onaseron | Onaset | Oncodex | Ondagen | Ondamax | Ondason | Onsat | Periset | Seton | Setronax | Vomiset</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ondansetron | Ondansetron accord | Ondansetron eg | Ondansetron hikma | Ondansetron sandoz | Ondansetron teva | Zofran | Zofsetron</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Ondamac | Ondansetron denk</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Emetron | Ondansetron b.braun | Zofran</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ansentron | Bienn | Bienn direct | Clor ondansetron | Cloridrato de ondansetrona | Emistop | Enavo odt | Injectrax | Jofix | Listo | Modifical | Nantron | Naudan odt | Nausedron | Nautex | Ondavon | Ontrax | Setronax | Volig | Vonau flash | Zofran | Zonax</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ondansetron accord | Ondansetron b. braun | Ondansetron Braun | Ondansetron fresenius | Ondansetron labatec | Ondansetron Mepha | Ondansetron nycomed | Ondansetron odt sandoz | Ondansetron sandoz | Ondansetron Teva | Ondansetron teva | Zofran</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">On.setron denk | Onset | Setronax</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Amilene | Emetix | Gardoton | Izofran | Levrox | Odatron | Ondanvitae | OTOC | Trorix</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">An si xin | Ang dan tong | Di li xin | Emeset | En nuo ping | Fu mi ting | Ondansetron | Ondansetron hydrochloride and glucose | Ou bei | Shu dan | Shun ji | Wei ze | Ya bang bei wei | Yi feng | Zofran | Zudan</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Aurodanz | Blokser | Bryterol | Cystron | Emenorm | Modifical | Omiwel | On.setron denk | Oncoemet | Ondansetron | Ondax | Ostasyn | Vonau flash | Zofran</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Emeset | Emetron | Novetron | Ondansetron Braun | Ondansetron ratiopharm | Ondansetron sandoz | Ondemet | Zofran</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Axisetron | Cellondan | Ondansetron | Ondansetron 1 a pharma | Ondansetron accord | Ondansetron Aurobindo | Ondansetron Aurus | Ondansetron b.braun | Ondansetron beta | Ondansetron bluefish | Ondansetron carinopharm | Ondansetron DeltaSelect | Ondansetron dura | Ondansetron ever pharma | Ondansetron Hameln | Ondansetron hexal | Ondansetron kabi | Ondansetron Lindopharm | Ondansetron Orca | Ondansetron pfizer | Ondansetron ratiopharm | Ondansetron sandoz | Ondansetron stada | Ondansetron tillomed | Ondansetron Vipharm | Ondansetron vitane | Ondansetron winthrop | Ondatron | Onsetron denk | Sigondan | Zofran</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Modifical | Ondansetron | Onone | Setron | Zofran</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Antivon | Bryterol | Modifical | Oncoemet | Ondansetron | Vonau flash | Zofran</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Emetron | Ondansetron accord | Ondansetron Bmm | Ondansetron claris | Ondansetron sandoz | Zofran</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Danofran | Danset | Emerest | Setronomet | Zofran</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Carvyx | Helmine | Ondansetron aristo | Ondansetron Aurovitas | Ondansetron bluefish | Ondansetron Braun | Ondansetron domac | Ondansetron fresenius kabi | Ondansetron Ips | Ondansetron Normon | Ondansetron Pharmacia | Ondansetron ratio | Ondansetron sandoz | Ondansetron serraclinics | Ondansetron stada | Ondansetron teva | Yatrox | Zofran</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Domi Up | Oberem | Ondansetron | Onsetron denk | Vomikind</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ondansetron accord | Ondansetron bluefish | Ondansetron bmm pharma | Ondansetron fresenius kabi | Ondansetron Hameln | Ondansetron hexal | Ondansetron stada | Ondansetron Synthon | Zofran</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ondansetron | Ondansetron Aguettant | Ondansetron arrow | Ondansetron biogaran | Ondansetron Dci | Ondansetron eg | Ondansetron Intas | Ondansetron kabi | Ondansetron Qualimed | Ondansetron ratiopharm | Ondansetron sandoz | Ondansetron Teva | Ondansetron winthrop | Ondansetron Zydus | Zophren</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ondansetron | Ondansetron pfizer | Ondansetron teva | Ondemet | Setofilm | Zofran</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Biosetron | Cruzafen | Dentron | Fedral | Nofail | Onda | Ondameton | Ondansetron Generics | Ondansetron/b.braun | Ondansetron/Generics | Ondansetron/kabi | Ondaren | Setrodan | Trondamet | Zodatron | Zofron</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo ondansetron | Ondansetron sandoz | Ondansetron teva | Pms Ondansetron | Setronax | Zofran</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Ondanzetron Kabi | Zofran</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Antivom | Emetron | Ondansetron ebewe | Ondansetron kabi | Ondansetron pfizer | Ondansetron pharmacenter | Ondansetron pliva | Ondansetron sandoz | Ondansetron-z | Oroset | Vomita | Zentron | Zofran</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cedantron | Ceteron | Dantroxal | Frazon | Fudanton | Insetron | Invomit | Kliran | Lametic | Lexatron | Narfoz | Odanostin | Ondane | Ondansetron | Ondansetron HCL | Ondarin | Ondavell | Onetic | Prezinton | Vomceran | Vometraz | Vometron | Vomigo | Zantron | Zofran</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Emizof | Ondansetron | Ondansetron claris | Ondansetron teva | Ondran | Zofran</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Zofran</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">4 On | Alset | Anset | Danotran | Danset | Deltron | Dioset md | Domi Up | Eden | Emcef | Emeban | Emekule | Emeran | Emesafe | Emeset | Emestop MD | Emeton | Emetosim | Emigo | Emitino | Emitron | Emitus | Emnil | Emnil md | Emset | Emsetron | Emtron | Entil | Eterna md | Flatron | Flexi | Glendan | Higo | Ht Blok | Isv | Lametic | Levom | Meristron | Myset | Myset md | Mytic | N tron md | Naucid | Nausedon | Nausehext | Nauseron | Nauset | Nausitroy | Neomit | Noem | Novatron | Nuavomin | O set | O.n.d. | Odanse | Oncotor | Ondace | Ondai | Ondamac | Ondanbic | Ondansetran | Ondanz | Ondar | Ondatab | Ondavom | Ondedom | Ondem | Ondem Md | Ondfast md | Ondisolv | Onditron | Ondoprez | Ondoray | Ondot | Onduro | Ondy md | Onkam | Onmed | Ono | Onset | Onsetrin | Onsett | Onsopil | Onstal | Onswift | Ontic | Ontix md | Oran | Oset | Osetron | Ozotron | Periset | Prospect | Rgnil | Satron | Set nv | Setiset | Setnorm | Setrona | Setronem | Shutem | Stop Em | Udan MD | Vegas | Vomalthea | Vomiban | Vomigo | Vomihalt | Vomikind | Vomilife | Vomiof | Vomipen | Vomirek | Vomirest | Vomirid md | Vomisave | Vomiset | Vomiz | Vorast | Vstop | Zenoset | Zofer | Zondan</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Ondisterain | Stop vomit</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Belofran | Ondansetron | Ondansetron Braun | Ondansetron Crinos | Ondansetron fresenius | Ondansetron hospira | Ondansetrone Dr. Reddy's | Ondansetrone Hikma | Ondansetrone Mylan | Ondansetrone Ranbaxy | Ondansetrone Teva | Zofran</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Nordaset | Onda | Ondansetron vianex | Setron-4 | Zemitron | Zofran</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ondansetron | Zofran</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Aurodanz | Emadon | Emeset | Emitino | Emitron | Onaseron | Ondansetron denk | Ondansetron Hameln | Ondavell | Ondavian | Ondazed | Ondem Md | Onderon | Onsett | Psm vomitino | Vomikind | Zofra odt | Zofran | Zofran zydis</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Hana ondansetron | Ondant | Ondaron | Onfran | Onseran | Onsetron | Zapron | Zofran | Zofran zydis</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Onda | Zofran</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo ondansetron | Emeset | Nausetron | Nozentrix | Ondansetron | Ondansetron arrow | Ondansetron biogaran | Ondansetron bluefish | Ondansetron hikma | Ondansetron medis | Setron | Trondamet | Zofran</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Emetron | Ondansetron | Ondansetron actiofarma | Ondansetron Aurobindo | Ondansetron Bmm | Ondansetron claris | Ondansetron sandoz | Setronon | Zofran</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Ondansetron b.braun | Zofran</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Emeset | Emetron | Ondansetron claris | Ondansetron kabi | Zofran</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Chemoset | Onset | Zofran | Zophren</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Antivon | Dosartron | Emistop | Ht Bloc | Krindor | Nevolnost | Ondansetron | Precirux | Setronax | Vylkor | Zincolset | Zofran</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo ondansetron | Emeset | Zofran</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Emitino | Ondansetron | Zofran</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ondansetron | Ondansetron A | Ondansetron actavis | Ondansetron Alpharma | Ondansetron bluefish | Ondansetron cf | Ondansetron fresenius kabi | Ondansetron ratiopharm | Ondansetron sandoz | Zofran | Zofran 4 zydis</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ondansetron | Ondansetron Aurobindo | Ondansetron bluefish | Ondansetron bmm pharma | Ondansetron fresenius kabi | Ondansetron Hameln | Ondansetron mayne | Ondansetron orifarm | Ondansetron pfizer | Zofran</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo ondansetron | Ondansetron | Ondansetron claris | Ondansetron dr Reddy | Ondansetron kabi | Onrex | Zofran</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Alencar | Modifical | Ondansetron | Onmek | Ontrona | Zofran</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Amnoset | Emistop | Enset 8 | Kabidan | Ondatrix | Onsett | Onsia | Onstal | Onstal forte | Onzet | Vometron | Zofran</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Adosetron | Anomed | Chemset | Danomed | Danset | Dansetron | Deston | Endtron | Nixvom | Odanex | Ondan | Ondanles | Ondansetron | Ondanz | Ondasave | Ondaset | Ondenles | Ondonix | Ongene | Onitron | Onrem | Onseron | Onset | Onvin | Osetron | Preset | Prevon | Sandem | Vemtix | Vominec | Zofran</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Atossa | Ebesetron | Emetron | Ondalek | Ondansetron accord | Ondansetron bluefish | Ondansetron Braun | Ondansetron claris | Ondansetron kabi | Ondaren | Setronon | Zofran</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ondansetron | Ondansetron HCL | Ondansetron odt | Zofran</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Emytron | Nausiend | Ondansetrom | Ondansetrom actavis | Ondansetrom Braun | Ondansetrom Ciclum | Ondansetrom generis | Ondansetrom hikma | Ondansetrom inibsa | Ondansetrom labesfal | Ondansetrom normon | Ondansetrom toLife | Otobrol | Zofran</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Espasevit | Kelme flash | Limine | Metasone | Ondansetron fusa | Ondansetron veinfar | Ondatron</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Dansetron | Ondan | Ondansetron Kabi | Ondavell | Vomet-Off | Vomiran | Zofran | Zofran Melt</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Osetron | Zofran</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Emeset | Emetron | Latran | Lazaran vm | Ondansetron | Ondansetron teva | Ondasol | Ondator | Ondavell | Osetron | Rondaset | Setronon | Vero ondansetron | Zofran</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo ondansetron | Emedan | Imatox | Kromafina | Ondanion | Ondansetron | Ondansetron kabi | Ondansetron medis | Pms Ondansetron | Zemitron | Zofran | Zofran melt | Zoron</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ondansetron abacus medicine | Ondansetron accord | Ondansetron alternova | Ondansetron amneal | Ondansetron Aurobindo | Ondansetron b braun | Ondansetron bluefish | Ondansetron bmm pharma | Ondansetron copyfarm | Ondansetron ebb | Ondansetron eql pharma | Ondansetron fresenius kabi | Ondansetron Hameln | Ondansetron hexal | Ondansetron hospira | Ondansetron mylan | Ondansetron nycomed | Ondansetron orifarm | Ondansetron pfizer | Ondansetron sandoz | Ondansetron stada | Ondansetron teva | Ondansetron vian | Zofran</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Ondansetron | Ondansetron sandoz | Ondavell | Zofran</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Onilat | Setronon | Zofran</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ondansetron b. braun | Ondansetron kabi | Ondansetron sandoz | Ondansetron teva | Ondemet | Onsetrogen | Setron | Zofran</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Emistop | Nautah | Onsia | Vomitron | Zetron | Zofran</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ondansetron | Ondansetron Renaudin | Zemitron</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Nauzex | Ondaren | Onzyd | Santis | Zofer | Zofran | Zoltem | Zontron | Zophralen</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ondan | Sopran | Vomiz | Zofran</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Emeset | Emesetron zdorovje | Emetron | Ondansetron | Ondansetron sandoz | Osetron | Setronon | Vomikind md | Zofetron | Zofran</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Aurodanz | Emitino | On.setron denk | Onsett | Vomistat | Vomiz</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Dasentron | Emivox | Izofran | Ondansetron | Ondatie | Quimiofran | Setron</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Emistop | Ondansetron | Ondasetron | Tructum | Vomigon | Zofran</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Dloe | Ondanov | Slandom</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aspetron | Austell ondansetron | Cipla ondansetron | Nausetron | Ondansetron | Vomiz | Zofer | Zofran</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Onsett</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Ondansetron fresenius | Onsett | Zofran</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-24807340">
<a name="24807340"></a>Abas MN, Tan PC, Azmi N, Omar SZ. Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. <i>Obstet Gynecol</i>. 2014;123(6):1272-1279.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/24807340/pubmed" id="24807340" target="_blank">24807340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29266076">
<a name="29266076"></a>ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin No. 189: nausea and vomiting of pregnancy. <i>Obstet Gynecol</i>. 2018;131(1):e15-e30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/29266076/pubmed" id="29266076" target="_blank">29266076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19602754">
<a name="19602754"></a>Afonso N, Dang A, Namshikar V, Kamat S, Rataboli PV. Intravenous ondansetron causing severe bradycardia: two cases. <i>Ann Card Anaesth</i>. 2009;12(2):172-173. doi:10.4103/0971-9784.53433<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/19602754/pubmed" id="19602754" target="_blank">19602754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28318209">
<a name="28318209"></a>Albert RH. End-of-life care: managing common symptoms. <i>Am Fam Physician</i>. 2017;95(6):356-361.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/28318209/pubmed" id="28318209" target="_blank">28318209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alexandraki.2019">
<a name="Alexandraki.2019"></a>Alexandraki I, Smetana GW. Acute viral gastroenteritis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31435648">
<a name="31435648"></a>Amant F, Berveiller P, Boere IA, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. <i>Ann Oncol</i>. 2019;30(10):1601-1612. doi:10.1093/annonc/mdz228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/31435648/pubmed" id="31435648" target="_blank">31435648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Andreoli.1">
<a name="Andreoli.1"></a>Andreoli CM, Gardiner MF. Open globe injuries: Emergency evaluation and initial management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 5, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22102545">
<a name="22102545"></a>Anderka M, Mitchell AA, Louik C, et al, "Medications Used to Treat Nausea and Vomiting of Pregnancy and the Risk of Selected Birth Defects," <i>Birth Defects Res A Clin Mol Teratol</i>, 2012, 94(1):22-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/22102545/pubmed" id="22102545" target="_blank">22102545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15190136">
<a name="15190136"></a>Apfel CC, Korttila K, Abdalla M, et al; IMPACT Investigators. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. <i>N Engl J Med</i>. 2004;350(24):2441-2451.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/15190136/pubmed" id="15190136" target="_blank">15190136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9578303">
<a name="9578303"></a>Applegate GL, Mittal BB, Kletzel M, et al. Outpatient total body irradiation prior to bone marrow transplantation in pediatric patients: a feasibility analysis. <i>Bone Marrow Transplant</i>. 1998;21(7):651-652.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/9578303/pubmed" id="9578303" target="_blank">9578303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20825792">
<a name="20825792"></a>Barrett TW, DiPersio DM, Jenkins CA, et al. A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults. <i>Am J Emerg Med</i>. 2011;29(3):247-255. doi: 10.1016/j.ajem.2009.09.028.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/20825792/pubmed" id="20825792" target="_blank">20825792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32471647">
<a name="32471647"></a>Benary D, Lozano JM, Higley R, Lowe D. Ondansetron prescription is associated with reduced return visits to the pediatric emergency department for children with gastroenteritis. <i>Ann Emerg Med</i>. 2020;76(5):625-634. doi:10.1016/j.annemergmed.2020.04.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/32471647/pubmed" id="32471647" target="_blank">32471647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33177330">
<a name="33177330"></a>Bollag L, Lim G, Sultan P, et al. Society for Obstetric Anesthesia and Perinatology: Consensus statement and recommendations for enhanced recovery after cesarean. <i>Anesth Analg</i>. 2021;132(5):1362-1377. doi:10.1213/ANE.0000000000005257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/33177330/pubmed" id="33177330" target="_blank">33177330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15727597">
<a name="15727597"></a>Bousquet PJ, Co-Minh HB, Demoly P. Isolated urticaria to ondansetron and successful treatment with granisetron. <i>Allergy</i>. 2005;60(4):543-544. doi:10.1111/j.1398-9995.2005.00754.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/15727597/pubmed" id="15727597" target="_blank">15727597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18304050">
<a name="18304050"></a>Braude D, Crandall C. Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial. <i>Acad Emerg Med</i>. 2008;15(3):209-215. doi: 10.1111/j.1553-2712.2008.00060.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/18304050/pubmed" id="18304050" target="_blank">18304050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12180111">
<a name="12180111"></a>Bredeson C, Perry G, Martens C, et al. Outpatient total body irradiation as a component of a comprehensive outpatient transplant program. <i>Bone Marrow Transplant</i>. 2002;29(8):667-671.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/12180111/pubmed" id="12180111" target="_blank">12180111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1485179">
<a name="1485179"></a>Bryson JC. Clinical safety of ondansetron. <i>Semin Oncol</i>. 1992;19(6 Suppl 15):26-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/1485179/pubmed" id="1485179" target="_blank">1485179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18503688">
<a name="18503688"></a>Bursztejn AC, Tréchot P, Cuny JF, Schmutz JL, Barbaud A. Cutaneous adverse drug reactions during chemotherapy: consider non-antineoplastic drugs. <i>Contact Dermatitis</i>. 2008;58(6):365-368. doi:10.1111/j.1600-0536.2007.01285.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/18503688/pubmed" id="18503688" target="_blank">18503688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23147521">
<a name="23147521"></a>Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L; American College of Gastroenterology clinical guideline: management of gastroparesis. <i>Am J Gastroenterol</i>. 2013;108(1):18-37. doi: 10.1038/ajg.2012.373.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/23147521/pubmed" id="23147521" target="_blank">23147521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Camilleri.2018">
<a name="Camilleri.2018"></a>Camilleri M. Treatment of gastroparesis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 21, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27986189">
<a name="27986189"></a>Campbell K, Rowe H, Azzam H, Lane CA. The management of nausea and vomiting of pregnancy. <i>J Obstet Gynaecol Can</i>. 2016;38(12):1127-1137. doi:10.1016/j.jogc.2016.08.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/27986189/pubmed" id="27986189" target="_blank">27986189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26345982">
<a name="26345982"></a>Celio L, Niger M, Ricchini F, Agustoni F. Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy. <i>Core Evid</i>. 2015;10:75-87. doi:10.2147/CE.S65555.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/26345982/pubmed" id="26345982" target="_blank">26345982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20040955">
<a name="20040955"></a>Chandrakala R, Vijayashankara CN, Kumar KK, Sarala N. Ondansetron induced fatal ventricular tachycardia. <i>Indian J Pharmacol</i>. 2008;40(4):186-187. doi:10.4103/0253-7613.43168<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/20040955/pubmed" id="20040955" target="_blank">20040955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15915019">
<a name="15915019"></a>Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. <i>Anesthesiology</i>. 2005;102(6):1094-1100. doi:10.1097/00000542-200506000-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/15915019/pubmed" id="15915019" target="_blank">15915019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18648229">
<a name="18648229"></a>Charbit B, Alvarez JC, Dasque E, Abe E, Démolis JL, Funck-Brentano C. Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study. <i>Anesthesiology</i>. 2008;109(2):206-212. doi:10.1097/ALN.0b013e31817fd8c8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/18648229/pubmed" id="18648229" target="_blank">18648229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8379613">
<a name="8379613"></a>Chen M, Tanner A, Gallo-Torres H. Anaphylactoid-anaphylactic reactions associated with ondansetron. <i>Ann Intern Med</i>. 1993;119(8):862. doi:10.7326/0003-4819-119-8-199310150-00026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/8379613/pubmed" id="8379613" target="_blank">8379613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16115266">
<a name="16115266"></a>Cherian A, Maguire M. Transient blindness following intravenous ondansetron. <i>Anaesthesia</i>. 2005;60(9):938-939. doi:10.1111/j.1365-2044.2005.04348.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/16115266/pubmed" id="16115266" target="_blank">16115266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25684821">
<a name="25684821"></a>Chilkoti G, Mohta M, Wadhwa R, Kumar M. The big "little problem" with postoperative nausea and vomiting prophylaxis. <i>Indian J Anaesth</i>. 2015;59(1):60-61. doi:10.4103/0019-5049.149464<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/25684821/pubmed" id="25684821" target="_blank">25684821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25461913">
<a name="25461913"></a>Cohen R, Shlomo M, Dil DN, Dinavitser N, Berkovitch M, Koren G. Intestinal obstruction in pregnancy by ondansetron. <i>Reprod Toxicol</i>. 2014;50:152-153. doi:10.1016/j.reprotox.2014.10.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/25461913/pubmed" id="25461913" target="_blank">25461913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15804995">
<a name="15804995"></a>Corapçioglu F, Sarper N. A prospective randomized trial of the antiemetic efficacy and cost-effectiveness of intravenous and orally disintegrating tablet of ondansetron in children with cancer. <i>Pediatr Hematol Oncol</i>. 2005;22(2):103-114. doi:10.1080/08880010590896468<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/15804995/pubmed" id="15804995" target="_blank">15804995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18762604">
<a name="18762604"></a>DeCamp LR, Byerley JS, Doshi N, Steiner MJ. Use of antiemetic agents in acute gastroenteritis: a systematic review and meta-analysis. <i>Arch Pediatr Adolesc Med</i>. 2008;162(9):858-865.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/18762604/pubmed" id="18762604" target="_blank">18762604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20921907">
<a name="20921907"></a>Demir HA, Batu ED, Yalçın B, Civelek E, Saçkesen C, Büyükpamukçu M. Anaphylactic reaction owing to ondansetron administration in a child with neuroblastoma and safe use of granisetron: a case report. <i>J Pediatr Hematol Oncol</i>. 2010;32(8):e341-e342. doi:10.1097/MPH.0b013e3181ea214a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/20921907/pubmed" id="20921907" target="_blank">20921907</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25935832">
<a name="25935832"></a>Diaz-Parlet J, Subramani S. Dystonic reaction associated with ondansetron administration in a patient with normal pressure hydrocephalus. <i>J Clin Anesth</i>. 2015;27(5):423-425. doi:10.1016/j.jclinane.2015.03.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/25935832/pubmed" id="25935832" target="_blank">25935832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33890993">
<a name="33890993"></a>Dormuth CR, Winquist B, Fisher A, et al; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Comparison of pregnancy outcomes of patients treated with ondansetron vs alternative antiemetic medications in a multinational, population-based cohort. <i>JAMA Netw Open</i>. 2021;4(4):e215329. doi:10.1001/jamanetworkopen.2021.5329<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/33890993/pubmed" id="33890993" target="_blank">33890993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23512831">
<a name="23512831"></a>Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/23512831/pubmed" id="23512831" target="_blank">23512831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24818542">
<a name="24818542"></a>Egerton-Warburton D, Meek R, Mee MJ, Braitberg G. Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo. <i>Ann Emerg Med</i>. 2014;64(5):526-532.e1. doi: 10.1016/j.annemergmed.2014.03.017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/24818542/pubmed" id="24818542" target="_blank">24818542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15327608">
<a name="15327608"></a>Einarson A, Maltepe C, Navioz Y, et al, "The Safety of Ondansetron for Nausea and Vomiting of Pregnancy: A Prospective Comparative Study," <i>BJOG</i>, 2004, 111(9):940-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/15327608/pubmed" id="15327608" target="_blank">15327608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25670522">
<a name="25670522"></a>Elkomy MH, Sultan P, Carvalho B, et al. Ondansetron pharmacokinetics in pregnant women and neonates: towards a new treatment for neonatal abstinence syndrome. <i>Clin Pharmacol Ther</i>. 2015;97(2):167-176. doi:10.1002/cpt.5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/25670522/pubmed" id="25670522" target="_blank">25670522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9703004">
<a name="9703004"></a>Farah RA, Aquino VM, Munoz LL, Sandler ES. Safety and cost-effectiveness of outpatient total body irradiation in pediatric patients undergoing stem cell transplantation. <i>J Pediatr Hematol Oncol</i>. 1998;20(4):319-321.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/9703004/pubmed" id="9703004" target="_blank">9703004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>FDA. FDA drug safety communication: new information regarding QT prolongation with ondansetron (Zofran). <a href="https://www.fda.gov/Drugs/DrugSafety/ucm310190.htm" target="_blank">https://www.fda.gov/Drugs/DrugSafety/ucm310190.htm</a>. Published June 29, 2012. Accessed July 10, 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Feinleib.1">
<a name="Feinleib.1"></a>Feinleib J, Kwan L, Yamani A. Postoperative nausea and vomiting. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19151059">
<a name="19151059"></a>Fernando SL, Broadfoot AJ. Ondansetron anaphylaxis: a case report and protocol for skin testing. <i>Br J Anaesth</i>. 2009;102(2):285-286. doi:10.1093/bja/aen376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/19151059/pubmed" id="19151059" target="_blank">19151059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22267256">
<a name="22267256"></a>Ferreira E, Gillet M, Lelièvre J, et al, "Ondansetron Use During Pregnancy: A Case Series," <i>J Popul Ther Clin Pharmacol</i>, 2012, 19(1):e1-e10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/22267256/pubmed" id="22267256" target="_blank">22267256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Feyer.1">
<a name="Feyer.1"></a>Feyer P, Jordan K. Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 5, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8708870">
<a name="8708870"></a>Fleisher DR. Management of cyclic vomiting syndrome. <i>J Pediatr Gastroenterol Nutr</i>. 1995;21 Suppl 1:S52-S56. doi:10.1097/00005176-199501001-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/8708870/pubmed" id="8708870" target="_blank">8708870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24314899">
<a name="24314899"></a>Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. <i>Ann Emerg Med</i>. 2014;64(1):19-25.e6. doi:10.1016/j.annemergmed.2013.10.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/24314899/pubmed" id="24314899" target="_blank">24314899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Furman.2018">
<a name="Furman.2018"></a>Furman JM, Barton JJS. Treatment of vertigo. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26411330">
<a name="26411330"></a>Furyk JS, Meek RA, Egerton-Warburton D. Drugs for the treatment of nausea and vomiting in adults in the emergency department setting. <i>Cochrane Database Syst Rev</i>. 2015;(9):CD010106. doi: 10.1002/14651858.CD010106.pub2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/26411330/pubmed" id="26411330" target="_blank">26411330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gallagher.2018">
<a name="Gallagher.2018"></a>Gallagher SA, Hackett P. Acute mountain sickness and high altitude cerebral edema. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 18, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32467512">
<a name="32467512"></a>Gan TJ, Belani KG, Bergese S, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. <i>Anesth Analg</i>. 2020;131(2):411-448. doi:10.1213/ANE.0000000000004833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/32467512/pubmed" id="32467512" target="_blank">32467512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24356162">
<a name="24356162"></a>Gan TJ, Diemunsch P, Habib AS, et al; Society for Ambulatory Anesthesia. Consensus guidelines for the management of postoperative nausea and vomiting. <i>Anesth Analg</i>. 2014;118(1):85-113. doi:10.1213/ANE.0000000000000002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/24356162/pubmed" id="24356162" target="_blank">24356162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716765">
<a name="23716765"></a>Ganjare A, Kulkarni AP. Comparative electrocardiographic effects of intravenous ondansetron and granisetron in patients undergoing surgery for carcinoma breast: a prospective single-blind randomised trial. <i>Indian J Anaesth</i>. 2013;57(1):41-45. doi:10.4103/0019-5049.108560<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/23716765/pubmed" id="23716765" target="_blank">23716765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26182691">
<a name="26182691"></a>García Núñez I, Algaba Mármol MA, Reina Ariza E. Ondansetron hypersensitivity: a clinical diagnosis protocol and cross-reactivity study. <i>J Investig Allergol Clin Immunol</i>. 2015;25(3):221-222.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/26182691/pubmed" id="26182691" target="_blank">26182691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24334242">
<a name="24334242"></a>Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. <i>Gut</i>. 2014;63(10):1617-1625. doi:10.1136/gutjnl-2013-305989<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/24334242/pubmed" id="24334242" target="_blank">24334242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18803119">
<a name="18803119"></a>George M, Al-Duaij N, O'Donnell KA, Shannon MW. Obtundation and seizure following ondansetron overdose in an infant. <i>Clin Toxicol (Phila)</i>. 2008;46(10):1064-1066. doi:10.1080/15563650802304401<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/18803119/pubmed" id="18803119" target="_blank">18803119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2151757">
<a name="2151757"></a>Gore S, Gilmore IT, Haigh CG, Brownless SM, Stockdale H, Morris AI. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. <i>Aliment Pharmacol Ther</i>. 1990;4(2):139-144. doi:10.1111/j.1365-2036.1990.tb00458.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/2151757/pubmed" id="2151757" target="_blank">2151757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26555872">
<a name="26555872"></a>Goyal P, Paramesh K, Puranik S, Proctor M, Sanghvi M. Delayed diagnosis of anaphylaxis secondary to ondansetron: a case report. <i>Eur J Anaesthesiol</i>. 2016;33(2):146-147. doi:10.1097/EJA.0000000000000372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/26555872/pubmed" id="26555872" target="_blank">26555872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22972112">
<a name="22972112"></a>Griffiths JD, Gyte GM, Paranjothy S, Brown HC, Broughton HK, Thomas J. Interventions for preventing nausea and vomiting in women undergoing regional anaesthesia for caesarean section. <i>Cochrane Database Syst Rev</i>. 2012;9(9):CD007579. doi: 10.1002/14651858.CD007579.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/22972112/pubmed" id="22972112" target="_blank">22972112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19453311">
<a name="19453311"></a>Grover VK, Mathew PJ, Hegde H. Efficacy of orally disintegrating ondansetron in preventing postoperative nausea and vomiting after laparoscopic cholecystectomy: a randomised, double-blind placebo controlled study. <i>Anaesthesia</i>. 2009;64(6):595-600. doi: 10.1111/j.1365-2044.2008.05860.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/19453311/pubmed" id="19453311" target="_blank">19453311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31540764">
<a name="31540764"></a>Gui S, Patel N, Issenman R, Kam AJ. Acute management of pediatric cyclic vomiting syndrome: a systematic review. <i>J Pediatr</i>. 2019;214:158-164.e4. doi:10.1016/j.jpeds.2019.06.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/31540764/pubmed" id="31540764" target="_blank">31540764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23635626">
<a name="23635626"></a>Habib AS, George RB, McKeen DM, et al. Antiemetics added to phenylephrine infusion during cesarean delivery: a randomized controlled trial. <i>Obstet Gynecol</i>. 2013;121(3):615-623. doi:10.1097/AOG.0b013e3182839fee<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/23635626/pubmed" id="23635626" target="_blank">23635626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22046106">
<a name="22046106"></a>Hafermann MJ, Namdar R, Seibold GE, Page RL 2nd. Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. <i>Drug Healthc Patient Saf</i>. 2011;3:53-58. doi:10.2147/DHPS.S25623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/22046106/pubmed" id="22046106" target="_blank">22046106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30702253">
<a name="30702253"></a>Hartman S, Brown E, Loomis E, Russell HA. Gastroenteritis in children. <i>Am Fam Physician</i>. 2019;99(3):159-165.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/30702253/pubmed" id="30702253" target="_blank">30702253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19261954">
<a name="19261954"></a>Havrilla PL, Kane-Gill SL, Verrico MM, Seybert AL, Reis SE. Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. <i>Ann Pharmacother</i>. 2009;43(3):532-536. doi:10.1345/aph.1L544<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/19261954/pubmed" id="19261954" target="_blank">19261954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HC.1">
<a name="HC.1"></a>Health Canada. Zofran (ondansetron) - dosage and administration of intravenous ondansetron in geriatrics (&gt;65 years of age) - for health professionals - recalls and safety alerts. <a href="http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/39943a-eng.php" target="_blank">http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/39943a-eng.php</a>. Published June 12, 2014. Accessed September 18, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hesketh.1">
<a name="Hesketh.1"></a>Hesketh PJ. Prevention of chemotherapy-induced nausea and vomiting in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 15, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8424909">
<a name="8424909"></a>Hewitt M, McQuade B, Stevens R. The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. <i>Clin Oncol (R Coll Radiol)</i>. 1993;5(1):11-14. doi:10.1016/s0936-6555(05)80686-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/8424909/pubmed" id="8424909" target="_blank">8424909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11054974">
<a name="11054974"></a>Holdsworth MT, Adams VR, Raisch DW, Wood JG, Winter SS. Computerized system for outcomes-based antiemetic therapy in children. <i>Ann Pharmacother</i>. 2000;34(10):1101-1108. doi:10.1345/aph.19410<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/11054974/pubmed" id="11054974" target="_blank">11054974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16404740">
<a name="16404740"></a>Holdsworth MT, Raisch DW, Frost J. Acute and delayed nausea and emesis control in pediatric oncology patients. <i>Cancer</i>. 2006;106(4):931-940.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/16404740/pubmed" id="16404740" target="_blank">16404740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28866307">
<a name="28866307"></a>Iammatteo M, Keskin T, Jerschow E. Evaluation of periprocedural hypersensitivity reactions. <i>Ann Allergy Asthma Immunol</i>. 2017;119(4):349-355.e2. doi:10.1016/j.anai.2017.07.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/28866307/pubmed" id="28866307" target="_blank">28866307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28860857">
<a name="28860857"></a>Jelting Y, Klein C, Harlander T, Eberhart L, Roewer N, Kranke P. Preventing nausea and vomiting in women undergoing regional anesthesia for cesarean section: challenges and solutions. <i>Local Reg Anesth</i>. 2017;10:83-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/28860857/pubmed" id="28860857" target="_blank">28860857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30849498">
<a name="30849498"></a>Kaplan YC, Richardson JL, Keskin-Arslan E, Erol-Coskun H, Kennedy D. Use of ondansetron during pregnancy and the risk of major congenital malformations: a systematic review and meta-analysis. <i>Reprod Toxicol</i>. 2019;86:1-13. doi:10.1016/j.reprotox.2019.03.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/30849498/pubmed" id="30849498" target="_blank">30849498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8596322">
<a name="8596322"></a>Kataja V, de Bruijn KM. Hypersensitivity reactions associated with 5- hydroxytryptamine(3)-receptor antagonists: a class effect?. <i>Lancet</i>. 1996;347(9001):584-585. doi:10.1016/s0140-6736(96)91275-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/8596322/pubmed" id="8596322" target="_blank">8596322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26770896">
<a name="26770896"></a>Kaul A, Kaul KK. Cyclic vomiting syndrome: a functional disorder. <i>Pediatr Gastroenterol Hepatol Nutr</i>. 2015;18(4):224-229. doi:10.5223/pghn.2015.18.4.224<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/26770896/pubmed" id="26770896" target="_blank">26770896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1386523">
<a name="1386523"></a>Kenny GN, Oates JD, Leeser J, et al. Efficacy of orally administered ondansetron in the prevention of postoperative nausea and vomiting: a dose ranging study. <i>Br J Anaesth</i>. 1992;68(5):466-470.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/1386523/pubmed" id="1386523" target="_blank">1386523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12585731">
<a name="12585731"></a>Khan RB. Migraine-type headaches in children receiving chemotherapy and ondansetron. <i>J Child Neurol</i>. 2002;17(11):857-858. doi:10.1177/08830738020170111706<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/12585731/pubmed" id="12585731" target="_blank">12585731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23675671">
<a name="23675671"></a>Kiesewetter B and Raderer M. Ondansetron for diarrhea associated with neuroendocrine tumors. <i>N Engl J Med.</i> 2013;368(20):1947-1948. doi:10.1056/NEJMc1301537.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/23675671/pubmed" id="23675671" target="_blank">23675671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23064917">
<a name="23064917"></a>Koren G, "Motherisk Update. Is Ondansetron Safe for Use During Pregnancy?" <i>Can Fam Physician</i>, 2012, 58(10):1092-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/23064917/pubmed" id="23064917" target="_blank">23064917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7803876">
<a name="7803876"></a>Kossey JL, Kwok KK. Anaphylactoid reactions associated with ondansetron. <i>Ann Pharmacother</i>. 1994;28(9):1029-1030. doi:10.1177/106002809402800906<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/7803876/pubmed" id="7803876" target="_blank">7803876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26795844">
<a name="26795844"></a>Kovács G, Wachtel AE, Basharova EV, Spinelli T, Nicolas P, Kabickova E. Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study. <i>Lancet Oncol</i>. 2016;17(3):332-344. doi:10.1016/S1470-2045(15)00520-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/26795844/pubmed" id="26795844" target="_blank">26795844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18573994">
<a name="18573994"></a>Kumar G, Hayes KA, Clark R. Efficacy of a scheduled IV cocktail of antiemetics for the palliation of nausea and vomiting in a hospice population. <i>Am J Hosp Palliat Care</i>. 2008;25(3):184-189. doi:10.1177/1049909108315909<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/18573994/pubmed" id="18573994" target="_blank">18573994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29754832">
<a name="29754832"></a>Lavecchia M, Chari R, Campbell S, Ross S. Ondansetron in pregnancy and the risk of congenital malformations: a systematic review. <i>J Obstet Gynaecol Can</i>. 2018;40(7):910-918. doi:10.1016/j.jogc.2017.10.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/29754832/pubmed" id="29754832" target="_blank">29754832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9358948">
<a name="9358948"></a>Lebrun C, Chichmanian RM, Peyrade F, Chatel M, Frenay M. Recurrent bowel occlusion with oral ondansetron with no side effects of the intravenous route: a previously unknown adverse event. <i>Ann Oncol</i>. 1997;8(9):919-920. doi:10.1023/a:1008205308867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/9358948/pubmed" id="9358948" target="_blank">9358948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29259513">
<a name="29259513"></a>Lee DY, Trinh T, Roy SK. Torsades de pointes after ondansetron infusion in 2 patients. <i>Tex Heart Inst J</i>. 2017;44(5):366-369. doi:10.14503/THIJ-16-6040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/29259513/pubmed" id="29259513" target="_blank">29259513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31860078">
<a name="31860078"></a>Lemon LS, Bodnar LM, Garrard W, et al. Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect. <i>Int J Epidemiol</i>. 2020;49(2):648-656. doi:10.1093/ije/dyz255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/31860078/pubmed" id="31860078" target="_blank">31860078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27374186">
<a name="27374186"></a>Lemon LS, Zhang H, Hebert MF, et al. Ondansetron exposure changes in a pregnant woman. <i>Pharmacotherapy</i>. 2016;36(9):e139-e141. doi: 10.1002/phar.1796.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/27374186/pubmed" id="27374186" target="_blank">27374186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24565629">
<a name="24565629"></a>Leung J, Guyer A, Banerji A. IgE-mediated hypersensitivity to ondansetron and safe use of palonosetron. <i>J Allergy Clin Immunol Pract</i>. 2013;1(5):526-527. doi:10.1016/j.jaip.2013.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/24565629/pubmed" id="24565629" target="_blank">24565629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18728540">
<a name="18728540"></a>Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. <i>J Pediatr Gastroenterol Nutr</i>. 2008;47(3):379-393.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/18728540/pubmed" id="18728540" target="_blank">18728540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30076469">
<a name="30076469"></a>Li BUK. Managing cyclic vomiting syndrome in children: beyond the guidelines. <i>Eur J Pediatr</i>. 2018b;177(10):1435-1442. doi:10.1007/s00431-018-3218-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/30076469/pubmed" id="30076469" target="_blank">30076469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29317399">
<a name="29317399"></a>Li K, Vo K, Lee BK, Addo N, Coralic Z. Effect of a single dose of i.v. ondansetron on QTc interval in emergency department patients. <i>Am J Health Syst Pharm</i>. 2018a;75(5):276-282. doi:10.2146/ajhp161070<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/29317399/pubmed" id="29317399" target="_blank">29317399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25303969">
<a name="25303969"></a>Macachor JD, Kurniawan M, Loganathan SB. Ondansetron-induced oculogyric crisis. <i>Eur J Anaesthesiol</i>. 2014;31(12):712-713. doi:10.1097/EJA.0000000000000169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/25303969/pubmed" id="25303969" target="_blank">25303969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30995461">
<a name="30995461"></a>Macones GA, Caughey AB, Wood SL, et al. Guidelines for postoperative care in cesarean delivery: Enhanced Recovery After Surgery (ERAS) Society recommendations (part 3). <i>Am J Obstet Gynecol</i>. 2019;221(3):247.e1-247.e9. doi:10.1016/j.ajog.2019.04.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/30995461/pubmed" id="30995461" target="_blank">30995461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29234184">
<a name="29234184"></a>Maitra A, Bhattacharyya S, Paik S, Pathak P, Tripathi SK. A rare case of fixed drug eruption due to ondansetron. <i>Iran J Med Sci</i>. 2017;42(5):497-500.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/29234184/pubmed" id="29234184" target="_blank">29234184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Maqbool.1">
<a name="Maqbool.1"></a>Maqbool A, Li BUK, Liacouras CA. Cyclic vomiting syndrome. In: Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020: chap. 369.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2137902">
<a name="2137902"></a>Marty M, Pouillart P, Scholl S, et al, “Comparison of the 5-hydroxytryptamine 3 (Serotonin) Antagonist Ondansetron (GR 38032F) With High-Dose Metoclopramide in the Control of Cisplatin-Induced Emesis,” <i>N Engl J Med</i>, 1990, 322(12):816-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/2137902/pubmed" id="2137902" target="_blank">2137902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26720490">
<a name="26720490"></a>Moffett PM, Cartwright L, Grossart EA, O'Keefe D, Kang CS. Intravenous ondansetron and the QT interval in adult emergency department patients: an observational study. <i>Acad Emerg Med</i>. 2016;23(1):102-105. doi:10.1111/acem.12836<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/26720490/pubmed" id="26720490" target="_blank">26720490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19798490">
<a name="19798490"></a>Mondick JT, Johnson BM, Haberer LJ, et al, "Population Pharmacokinetics of Intravenous Ondansetron in Oncology and Surgical Patients Aged 1-48 Months,"<i> Eur J Clin Pharmacolm</i>, 2010, 66(1):77-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/19798490/pubmed" id="19798490" target="_blank">19798490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moskowitz.1">
<a name="Moskowitz.1"></a>Moskowitz HS, Dinces EA. Meniere disease: Evaluation, diagnosis, and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25147175">
<a name="25147175"></a>Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. <i>Am J Health Syst Pharm</i>. 2014;71(17):1500-1508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/25147175/pubmed" id="25147175" target="_blank">25147175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. Published September 3, 2014. Accessed October 23, 2020. https://www.nice.org.uk/guidance/cg183
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12921512">
<a name="12921512"></a>Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. <i>Ann Pharmacother</i>. 2003;37(9):1276-1286. doi:10.1345/aph.1C510<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/12921512/pubmed" id="12921512" target="_blank">12921512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27410922">
<a name="27410922"></a>Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. <i>N Engl J Med</i>. 2016;375(2):134-142. doi: 10.1056/NEJMoa1515725.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/27410922/pubmed" id="27410922" target="_blank">27410922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25040518">
<a name="25040518"></a>Neoh K, Adkinson L, Montgomery V, Hurlow A. Management of nausea and vomiting in palliative care. <i>Br J Hosp Med (Lond)</i>. 2014;75(7):391-392, 394-396. doi:10.12968/hmed.2014.75.7.391<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/25040518/pubmed" id="25040518" target="_blank">25040518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20942670">
<a name="20942670"></a>Niebyl JR. Clinical practice. Nausea and vomiting in pregnancy [published correction appears in <i>N Engl J Med</i>. 2010;363(21):2078]. <i>N Engl J Med</i>. 2010;363(16):1544-1550. doi: 10.1056/NEJMcp1003896.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/20942670/pubmed" id="20942670" target="_blank">20942670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32132152">
<a name="32132152"></a>Niño-Serna LF, Acosta-Reyes J, Veroniki AA, Florez ID. Antiemetics in children with acute gastroenteritis: a meta-analysis. <i>Pediatrics</i>. 2020;145(4):e20193260. doi:10.1542/peds.2019-3260<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/32132152/pubmed" id="32132152" target="_blank">32132152</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15813840">
<a name="15813840"></a>O'Donohue JW, Pereira SP, Ashdown AC, Haigh CG, Wilkinson JR, Williams R. A controlled trial of ondansetron in the pruritus of cholestasis. <i>Aliment Pharmacol Ther</i>. 2005;21(8):1041-1045. doi:10.1111/j.1365-2036.2005.02430.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/15813840/pubmed" id="15813840" target="_blank">15813840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25198265">
<a name="25198265"></a>Oliveira LG, Capp SM, You WB, Riffenburgh RH, Carstairs SD. Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial. <i>Obstet Gynecol</i>. 2014;124(4):735-742.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/25198265/pubmed" id="25198265" target="_blank">25198265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9006746">
<a name="9006746"></a>Olver I, Paska W, Depierre A, et al. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. <i>Ann Oncol</i>. 1996;7(9):945-952. doi:10.1093/oxfordjournals.annonc.a010798<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/9006746/pubmed" id="9006746" target="_blank">9006746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MajorPharmaceuticals.1">
<a name="MajorPharmaceuticals.1"></a>Ondansetron Hydrochloride oral solution, USP (ondansetron hydrochloride) oral [prescribing information]. Eatontown, NJ: West Ward Pharmaceuticals Corp; September 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SunPharmaceutical.1">
<a name="SunPharmaceutical.1"></a>Ondansetron hydrochloride tablet [prescribing information]. Cranbury, NJ: Dr Reddy's Laboratories Limited; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AuroMedics.1">
<a name="AuroMedics.1"></a>Ondansetron injection (ondansetron hydrochloride) IV or IM [prescribing information]. E. Windsor, NJ: AuroMedics Pharma LLC; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nexus.1">
<a name="Nexus.1"></a>Ondansetron injection [summary of product characteristics]. Gloucester, UK: Nexus; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Amneal.1">
<a name="Amneal.1"></a>Ondansetron oral solution [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18633020">
<a name="18633020"></a>Pan PH, Lee SC, Harris LC. Antiemetic prophylaxis for postdischarge nausea and vomiting and impact on functional quality of living during recovery in patients with high emetic risks: a prospective, randomized, double-blind comparison of two prophylactic antiemetic regimens. <i>Anesth Analg</i>. 2008;107(2):429-38. doi: 10.1213/ane.0b013e318172f992.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/18633020/pubmed" id="18633020" target="_blank">18633020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23445092">
<a name="23445092"></a>Pasternak B, Svanström H, and Hviid A, "Ondansetron in Pregnancy and Risk of Adverse Fetal Outcomes," <i>N Engl J Med</i>, 2013, 368(9):814-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/23445092/pubmed" id="23445092" target="_blank">23445092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20022195">
<a name="20022195"></a>Patanwala AE, Amini R, Hays DP, Rosen P. Antiemetic therapy for nausea and vomiting in the emergency department. <i>J Emerg Med</i>. 2010;39(3):330-336. doi:10.1016/j.jemermed.2009.08.060.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/20022195/pubmed" id="20022195" target="_blank">20022195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31428390">
<a name="31428390"></a>Patel E, Rosemond D, Afzal A. Ondansetron induced <i>torsades de pointes</i>. <i>Clin Case Rep</i>. 2019;7(8):1557-1558. doi:10.1002/ccr3.2251<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/31428390/pubmed" id="31428390" target="_blank">31428390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36221901">
<a name="36221901"></a>Patel P, Robinson PD, Cohen M, et al. Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: a clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2022;69(12):e30001. doi:10.1002/pbc.30001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/36221901/pubmed" id="36221901" target="_blank">36221901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37178438">
<a name="37178438"></a>Patel P, Robinson PD, Phillips R, et al. Treatment of breakthrough and prevention of refractory chemotherapy-induced nausea and vomiting in pediatric cancer patients: clinical practice guideline update. <i>Pediatr Blood Cancer</i>. 2023;70(8):e30395. doi:10.1002/pbc.30395<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/37178438/pubmed" id="37178438" target="_blank">37178438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21691464">
<a name="21691464"></a>Patka J, Wu DT, Abraham P, Sobel RM. Randomized controlled trial of ondansetron vs. prochlorperazine in adults in the emergency department. <i>West J Emerg Med</i>. 2011;12(1):1-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/21691464/pubmed" id="21691464" target="_blank">21691464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16009690">
<a name="16009690"></a>Piche T, Vanbiervliet G, Cherikh F, et al. Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study. <i>Gut</i>. 2005;54(8):1169-1173. doi:10.1136/gut.2004.055251<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/16009690/pubmed" id="16009690" target="_blank">16009690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32420702">
<a name="32420702"></a>Picot C, Berard A, Grenet G, Ripoche E, Cucherat M, Cottin J. Risk of malformation after ondansetron in pregnancy: An updated systematic review and meta-analysis. <i>Birth Defects Res</i>. Published online 2020. doi:10.1002/bdr2.1705<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/32420702/pubmed" id="32420702" target="_blank">32420702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1375972">
<a name="1375972"></a>Platt AJ, Heddle RM, Rake MO, et al. Ondansetron in carcinoid syndrome. <i>Lancet</i>. 1992;339(8806):1416.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/1375972/pubmed" id="1375972" target="_blank">1375972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24590374">
<a name="24590374"></a>Popovic M, Warr DG, Deangelis C, et al. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. <i>Support Care Cancer</i>. 2014;22(6):1685-1697. doi: 10.1007/s00520-014-2175-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/24590374/pubmed" id="24590374" target="_blank">24590374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1702012">
<a name="1702012"></a>Priestman TJ, Roberts JT, Lucraft H, et al. Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. <i>Clin Oncol (R Coll Radiol)</i>. 1990;2(2):71-75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/1702012/pubmed" id="1702012" target="_blank">1702012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8305355">
<a name="8305355"></a>Priestman TJ, Roberts JT, Upadhyaya BK. A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy. <i>Clin Oncol (R Coll Radiol)</i>. 1993;5(6):358-363.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/8305355/pubmed" id="8305355" target="_blank">8305355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34560688">
<a name="34560688"></a>Rajan N, Joshi GP. Management of postoperative nausea and vomiting in adults: current controversies. <i>Curr Opin Anaesthesiol</i>. 2021;34(6):695-702. doi:10.1097/ACO.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/34560688/pubmed" id="34560688" target="_blank">34560688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27729680">
<a name="27729680"></a>Rapp JH, Yuen M, Abraham T. Bradycardia after intravenous ondansetron with asystole on rechallenge: a case report. <i>Hosp Pharm</i>. 2015;50(10):918-921. doi:10.1310/hpj5010-918<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/27729680/pubmed" id="27729680" target="_blank">27729680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21589830">
<a name="21589830"></a>Rerksuppaphol S, Rerksuppaphol L. Efficacy of intravenous ondansetron to prevent vomiting episodes in acute gastroenteritis: a randomized, double blind, and controlled trial. <i>Pediatr Rep</i>. 2010;2(2):e17. doi:10.4081/pr.2010.e17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/21589830/pubmed" id="21589830" target="_blank">21589830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7723573">
<a name="7723573"></a>Rice GP, Ebers GC. Ondansetron for intractable vertigo complicating acute brainstem disorders. <i>Lancet</i>. 1995;345(8958):1182-1183.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/7723573/pubmed" id="7723573" target="_blank">7723573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12962170">
<a name="12962170"></a>Ritter MJ, Goodman BP, Sprung J, Wijdicks EF. Ondansetron-induced multifocal encephalopathy. <i>Mayo Clin Proc</i>. 2003;78(9):1150-1152. doi:10.4065/78.9.1150<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/12962170/pubmed" id="12962170" target="_blank">12962170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7586904">
<a name="7586904"></a>Roila F, Del Favero A. Ondansetron clinical pharmacokinetics. <i>Clin Pharmacokinet</i>. 1995;29(2):95-109. doi:10.2165/00003088-199529020-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/7586904/pubmed" id="7586904" target="_blank">7586904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8265095">
<a name="8265095"></a>Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group [published correction appears in <i>Oncology</i>. 1994;51(3):243]. <i>Oncology</i>. 1994;51(1):113-118. doi:10.1159/000227321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/8265095/pubmed" id="8265095" target="_blank">8265095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33754455">
<a name="33754455"></a>Ruktrirong J, Traivaree C, Monsereenusorn C, Photia A, Lertvivatpong N, Rujkijyanont P. Single daily dosing versus divided dosing intravenous ondansetron to prevent chemotherapy-induced nausea and vomiting among children: A comparative randomized double-blind controlled trial. <i>Pediatr Blood Cancer</i>. Published online March 23, 2021. doi:10.1002/pbc.29002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/33754455/pubmed" id="33754455" target="_blank">33754455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28882877">
<a name="28882877"></a>Rutman L, Klein EJ, Brown JC. Clinical pathway produces sustained improvement in acute gastroenteritis care. <i>Pediatrics</i>. 2017;140(4):e20164310. doi:10.1542/peds.2016-4310<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/28882877/pubmed" id="28882877" target="_blank">28882877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30268346">
<a name="30268346"></a>Saberi A, Pourshafie SH, Kazemnejad-Leili E, Nemati S, Sutohian S, Sayad-Fathi S. Ondansetron or promethazine: which one is better for the treatment of acute peripheral vertigo? <i>Am J Otolaryngol</i>. 2019;40(1):10-15. doi:10.1016/j.amjoto.2018.09.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/30268346/pubmed" id="30268346" target="_blank">30268346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21091329">
<a name="21091329"></a>Salvucci AA, Squire B, Burdick M, Luoto M, Brazzel D, Vaezazizi R. Ondansetron is safe and effective for prehospital treatment of nausea and vomiting by paramedics. <i>Prehosp Emerg Care</i>. 2011;15(1):34-38. doi: 10.3109/10903127.2010.519822.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/21091329/pubmed" id="21091329" target="_blank">21091329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24803784">
<a name="24803784"></a>Samanta S, Jain K, Samanta S, Ghatak T. Intraoperative pulseless ventricular tachycardia after Ondansetron. <i>J Anaesthesiol Clin Pharmacol</i>. 2014;30(2):293-294. doi:10.4103/0970-9185.130123<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/24803784/pubmed" id="24803784" target="_blank">24803784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10370357">
<a name="10370357"></a>Sandoval C, Corbi D, Strobino B, Fevzi Ozkaynak M, Tugal O, Jayabose S. Randomized double-blind comparison of single high-dose ondansetron and multiple standard-dose ondansetron in chemotherapy-naive pediatric oncology patients. <i>Cancer Invest</i>. 1999;17(5):309-313. doi:10.3109/07357909909032871<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/10370357/pubmed" id="10370357" target="_blank">10370357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23248379">
<a name="23248379"></a>Saraogi PP, Nayak CS, Pereira RR, Dhurat RS. Inadvertent provocative oral ondansetron use leading to toxic epidermal necrolysis in an HIV-infected patient. <i>Indian J Dermatol</i>. 2012;57(6):503. doi:10.4103/0019-5154.103082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/23248379/pubmed" id="23248379" target="_blank">23248379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7717328">
<a name="7717328"></a>Schwörer H, Münke H, Stöckmann F, Ramadori G. Treatment of diarrhea in carcinoid syndrome with ondansetron, tropisetron, and clonidine. <i>Am J Gastroenterol</i>. 1995;90(4):645-648.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/7717328/pubmed" id="7717328" target="_blank">7717328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1386245">
<a name="1386245"></a>Seynaeve C, Schuller J, Buser K, et al, “Comparison of the Anti-emetic Efficacy of Different Doses of Ondansetron, Given as Either a Continuous Infusion or a Single Intravenous Dose, in Acute Cisplatin-Induced Emesis,” <i>Br J Cancer</i> 1992, 66(1):192-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/1386245/pubmed" id="1386245" target="_blank">1386245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20043218">
<a name="20043218"></a>Sharma R, Panda A. Ondansetron-induced headache in a parturient mimicking postdural puncture headache. <i>Can J Anaesth</i>. 2010;57(2):187-188. doi:10.1007/s12630-009-9226-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/20043218/pubmed" id="20043218" target="_blank">20043218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20661681">
<a name="20661681"></a>Singh V, Sinha A, Prakash N. Ondansetron-induced migraine-type headache. <i>Can J Anaesth</i>. 2010;57(9):872-873. doi:10.1007/s12630-010-9350-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/20661681/pubmed" id="20661681" target="_blank">20661681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16584287">
<a name="16584287"></a>Siu SS, Chan MT, and Lau TK, "Placental Transfer of Ondansetron During Early Human Pregnancy," <i>Clin Pharmacokinet</i>, 2006, 45(4):419-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/16584287/pubmed" id="16584287" target="_blank">16584287</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Smith.1">
<a name="Smith.1"></a>Smith JA, Fox KA. Nausea and vomiting of pregnancy: Treatment and outcome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 11, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10388135">
<a name="10388135"></a>Spector JI, Lester EP, Chevlen EM, et al, “A Comparison of Oral Ondansetron and Intravenous Granisetron for the Prevention of Nausea and Emesis Associated With Cisplatin-Based Chemotherapy,” <i>Oncologist</i>, 1998, 3(6):432-438.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/10388135/pubmed" id="10388135" target="_blank">10388135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12100220">
<a name="12100220"></a>Spiller R. Serotonergic modulating drugs for functional gastrointestinal diseases. <i>Br J Clin Pharmacol</i>. 2002;54(1):11-20. doi:10.1046/j.1365-2125.2002.01612.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/12100220/pubmed" id="12100220" target="_blank">12100220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10918432">
<a name="10918432"></a>Spitzer TR, Friedman CJ, Bushnell W, Frankel SR, Raschko J. Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation. <i>Bone Marrow Transplant</i>. 2000;26(2):203-210.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/10918432/pubmed" id="10918432" target="_blank">10918432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12707136">
<a name="12707136"></a>Sprung J, Choudhry FM, Hall BA. Extrapyramidal reactions to ondansetron: cross-reactivity between ondansetron and prochlorperazine?. <i>Anesth Analg</i>. 2003;96(5):1374-1376. doi:10.1213/01.ane.0000058845.72102.f2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/12707136/pubmed" id="12707136" target="_blank">12707136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25659986">
<a name="25659986"></a>Svanberg A, Birgegård G. Addition of aprepitant (Emend) to standard antiemetic regimen continued for 7 days after chemotherapy for stem cell transplantation provides significant reduction of vomiting. <i>Oncology</i>. 2015;89(1):31-36. doi: 10.1159/000371523.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/25659986/pubmed" id="25659986" target="_blank">25659986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2138532">
<a name="2138532"></a>Talley NJ, Phillips SF, Haddad A, et al. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. <i>Dig Dis Sci</i>. 1990;35(4):477-480. doi:10.1007/BF01536922<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/2138532/pubmed" id="2138532" target="_blank">2138532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21679335">
<a name="21679335"></a>Tan J, Mehr S. Anaphylaxis to an ondansetron wafer. <i>J Paediatr Child Health</i>. 2012;48(6):543-544. doi:10.1111/j.1440-1754.2011.02124.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/21679335/pubmed" id="21679335" target="_blank">21679335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21297474">
<a name="21297474"></a>Tan PC and Omar SZ, "Contemporary Approaches to Hyperemesis During Pregnancy," <i>Curr Opin Obstet Gynecol</i>, 2011, 23(2):87-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/21297474/pubmed" id="21297474" target="_blank">21297474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15915460">
<a name="15915460"></a>Theal JJ, Toosi MN, Girlan L, et al. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. <i>Hepatology</i>. 2005;41(6):1305-1312. doi:10.1002/hep.20698<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/15915460/pubmed" id="15915460" target="_blank">15915460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27387786">
<a name="27387786"></a>Trivedi S, Schiltz B, Kanipakam R, Bos JM, Ackerman MJ, Ouellette Y. Effect of ondansetron on QT interval in patients cared for in the PICU. <i>Pediatr Crit Care Med</i>. 2016;17(7):e317-e323. doi:10.1097/PCC.0000000000000776<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/27387786/pubmed" id="27387786" target="_blank">27387786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7664768">
<a name="7664768"></a>Veneziano M, Framarino Dei Malatesta M, Bandiera AF, Fiorelli C, Galati M, Paolucci A. Ondansetron-induced headache. Our experience in gynecological cancer. <i>Eur J Gynaecol Oncol</i>. 1995;16(3):203-207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/7664768/pubmed" id="7664768" target="_blank">7664768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31241819">
<a name="31241819"></a>Venkatesan T, Levinthal DJ, Tarbell SE, et al. Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association. <i>Neurogastroenterol Motil</i>. 2019;31(suppl 2):e13604. doi:10.1111/nmo.13604<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/31241819/pubmed" id="31241819" target="_blank">31241819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33075160">
<a name="33075160"></a>Weibel S, Rücker G, Eberhart LH, et al. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis. <i>Cochrane Database Syst Rev</i>. 2020;10(10):CD012859. doi:10.1002/14651858.CD012859.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/33075160/pubmed" id="33075160" target="_blank">33075160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11575988">
<a name="11575988"></a>Weiss KS. Anaphylactic reaction to ondansetron. <i>Arch Intern Med</i>. 2001;161(18):2263. doi:10.1001/archinte.161.18.2263<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/11575988/pubmed" id="11575988" target="_blank">11575988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10989464">
<a name="10989464"></a>White L, Daly SA, McKenna CJ, et al. A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy. <i>Pediatr Hematol Oncol</i>. 2000;17(6):445-455. doi:10.1080/08880010050120791<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/10989464/pubmed" id="10989464" target="_blank">10989464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>WHO Pharmaceuticals Newsletter. Ondansetron and serotonin syndrome. 2012; 3:16-21.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9849494">
<a name="9849494"></a>Wymenga AN, de Vries EG, Leijsma MK, Kema IP, Kleibeuker JH. Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome. <i>Eur J Cancer</i>. 1998;34(8):1293-1294.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/9849494/pubmed" id="9849494" target="_blank">9849494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28856920">
<a name="28856920"></a>Zhou C, Zhu Y, Bao Z, Wang X, Liu Q. Efficacy of ondansetron for spinal anesthesia during cesarean section: a meta-analysis of randomized trials. <i>J Int Med Res</i>. 2018;46(2):654-662. doi:10.1177/0300060517716502<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/28856920/pubmed" id="28856920" target="_blank">28856920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zofran.1">
<a name="Zofran.1"></a>Zofran injection (ondansetron) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ZofranODT.1">
<a name="ZofranODT.1"></a>Zofran ODT (ondansetron, USP) [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zofran.2">
<a name="Zofran.2"></a>Zofran tablets and oral solution and Zofran ODT orally disintegrating tablets (ondansetron) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zuplenz.1">
<a name="Zuplenz.1"></a>Zuplenz (ondansetron) [prescribing information]. Warren, NJ: Aquestive Therapeutics; August 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12659 Version 711.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
